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 Parkinson’s disease (PD) is the second most common neurodegenerative disease 
worldwide and afflicts approximately 1% of individuals over age 65. The dementia that 
develops in association with PD is devastating to both the patient and their family and 
common, with more than 80% of individuals with PD developing dementia by 15 years 
after symptom onset. Current treatments for both PD and PD-dementia (PDD) have 
unacceptable side effects and there are no disease modifying therapies.  An improved 
understanding of the pathophysiology of PD and PDD, however, is leading to testing of 
therapeutics that are targeted to specific pathways that have been implicated in PD 
pathophysiology. This pathophysiology is reviewed in Chapter 1, with an emphasis in the 
c-Abl molecule pathways role in PD pathophysiology. A biomarker for both PD and PDD 
would greatly improve our diagnosis, prognosis, and potentially the efficacy of these new 
treatment trials.   Chapter 2 therefore considers whether poly (ADP-ribose), a molecule 
downstream in the c-Abl pathway, is a potential biomarker for PDD. Finally, we need to 
improve the outcomes for our current patients and Chapter 3 explores the role of a 
modifiable risk factor, namely vascular disease and subsequent vascular pathology, in the 
development of PDD. Together, these investigations broaden our understanding of PDD 
and are a step toward improved treatment for individuals with this devastating disease. 
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I: Pathophysiology and current treatment of Parkinson’s disease (PD) 


















Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
affecting approximately 1% of the population over the age of 65.  With the aging 
population and improving medical treatment, the number of individuals with PD is 
expected to grow from its current level of more than 4.5 million people worldwide to 
more than 8 million people by 2030 (Dorsey et al., 2007). Approximately 1/3 of 
individuals with PD have PD- dementia (PDD), with another subset of individuals 
experiencing PD-related mild cognitive impairment (Aarsland & Kurz, 2010). Individuals 
with PD are less likely to work, have higher nursing home placement and greater 
mortality than the general population and those with PDD have worse outcomes than 
those with PD alone (Aarsland, Larsen, Tandberg, & Laake, 2000).  
PD is a chronic progressive disorder manifested by at least two of the four motor 
signs of tremor at rest, bradykinesia, rigidity and postural instability and results from the 
selective degeneration of the nigrostriatal pathway that provides dopaminergic 
innervation to the striatum. PDD is applied to individuals who develop dementia in the 
setting of a PD diagnosis and case series that followed patients through 15 years after 
symptom onset found a cumulative incidence of PDD of about 80% of the PD population 
(Aarsland, Andersen, Larsen, Lolk, & Kragh-Sorensen, 2003). PD is currently diagnosed 
based on patient history and a clinical examination showing the presence of Parkinson’s 
motor signs, coupled with no or minimal “red flags” that indicate atypical parkinsonism 
(i.e. slow or absent vertical saccades) or other exclusion criteria (i.e. history of repeated 
strokes or long term exposure to specific medications) (Hughes, Daniel, Kilford, & Lees, 
1992; Postuma et al., 2018). Using these diagnostic methods, autopsy series have shown 
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that even movement disorder specialists are incorrect about the diagnosis of PD 
approximately 10% of the time (Hughes et al., 1992). Furthermore, it is unfortunately not 
unusual for patients to have an up to 2-year delay between symptom onset and diagnosis. 
Diagnosis is complicated by two primary factors. 1) The phenotypic heterogeneity of the 
disease and 2) the phenotypic overlap between PD and many of the atypical 
parkinsonisms. In other words, parkinsonism and the associated degeneration of the 
nigrostriatral circuitry is a final common pathway of neurodegeneration caused by 
different abnormal proteins including synucleinopathies such as multiple system atrophy 
(MSA), Dementia with Lewy Bodies (DLB), and PD and tauopathies such as Progressive 
Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS) and even Alzheimer’s disease 
(AD). Definitive diagnosis of PD can only occur based on autopsy tissue that shows the 
presence of α-synuclein, the presence of eosinophilic, intracytoplasmic proteinaceous 
inclusions termed Lewy bodies (LBs) with alpha-synuclein inside them, and dystrophic 
Lewy neurites (LNs) in surviving nigral neurons (McKeith et al., 2017) 
Although the cardinal symptoms of PD can be improved using currently available 
dopamine replacement strategies, many of these treatments have unacceptable side 
effects and many of the non-motor features of the disease have minimal treatments. Most 
importantly, treatments that provide neuroprotection and/or disease modifying effects are 
an urgent unmet clinical need. Development of these new therapeutics requires looking at 
the challenge from multiple perspectives, including improving our understanding 
regarding the pathophysiology of PD and the identification of progression biomarkers for 
PD. We also need to take a similarly multi-pronged approach to the development of 
disease modifying therapeutics for PDD, recognizing that development of PDD is 
 
 4 
multifactorial such that many but not all of the therapeutics for PD will likely improve 
PDD.  
Two critical steps toward development of these disease modifying therapeutics for 
PDD are 1) better understanding of the pathologic heterogeneity of and pathologic 
contributors to PDD and 2) identification of progression markers that are predictive of 
speed of progression as well as the makeup of the underlying pathophysiology. 
Development of PDD is certainly dependent on the alpha-synuclein pathology that is the 
hallmark of PD but PDD development is also influenced by the tau and amyloid beta 
pathology ((Irwin, Lee, & Trojanowski, 2013; Irwin et al., 2012)). While vascular disease 
contributions to dementia have been well-documented, the importance of vascular disease 
and associated vascular risk factors for the development of PDD is less clear. Since 
vascular risk factors are modifiable, determination of whether vascular disease is 
associated with development of PDD has direct and immediate impact on patient care. In 
addition, should vascular disease be shown to contribute to development of PDD, 
treatment of vascular disease among our patients becomes even more critical and it opens 
the door to investigation of vascular biomarkers.  We can also seek out biomarkers 
amongst currently known PD pathways, including the parthanatos cell death pathway. 
These biomarkers will point to the potential efficacy of therapeutics that are under 
development or approved for a number of different cancers, including c-Abl inhibitors 
and poly (ADP-ribose) polymerase 1 (PARP1) inhibitors.  
In this review, we discuss the current state of PD diagnosis and management, with 
a focused discussion of abnormal alpha-synuclein and parthanatos as part of PD 
pathophysiology. We also discuss the spread of this abnormal alpha-synuclein within the 
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brain  and finally there is a brief discussion regarding the environmental contributors to 
PD pathophysiology. Together, this improved understanding of the many facets of PD 
pathophysiology seeks to pave the way to more effective and efficient diagnosis of PD 
and to meet our goal of halting disease progression. 
 
Review of current therapeutics 
The current treatment of PD is solely based on symptomatic management. 
Effective treatment is therefore individualized, within the guidelines of the evidence-
based practices discussed below.  Patients experience varying degrees of symptoms, with 
some having more rapid motor impairments while some experience severe psychiatric 
symptomatology. Put together, this phenotypic heterogeneity is one of the many 
challenges to diagnosis, treatment, and to the identification of disease modifying 
therapies.  
Treatment of motor symptoms of PD  
The mainstay treatment for the motor complications of PD remains dopamine 
replacement, usually in the form of levodopa. Levodopa was first given to patients in 
1961, with growing recognition of its efficacy through the 1960s and the addition of a 
dopa decarboxylase inhibitor in the early 1970s  (Tolosa, Marti, Valldeoriola, & 
Molinuevo, 1998). Carbidopa/levodopa remains the most effective medication for 
treating the motoric symptoms of PD. Unfortunately, about 50% of patients develop 
dyskinesias within about 5 years of treatment  (Rascol et al., 2000). Additionally,  over 
time the therapeutic window of the medication narrows (Olanow, Obeso, & Stocchi, 
2006), necessitating increased frequency and amount of dosing. Much of the 
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development of new medications in PD has focused on improving the motor fluctuations, 
dyskinesias, due to this narrowing of the therapeutic window. A new oral formulation of 
carbidopa/levodopa was FDA approved in January 2015. Marketed under the brand name 
Rytary, it contains both control release and immediate release carbidopa/levodopa. 
Patients therefore take the medication about 3-4 times a day, as opposed to the current 
carbidopa/levodopa with which patients may eventually require as many as 7-10 doses a 
day.  Carbidopa/levodopa intestinal gel, FDA approved in 2015, follows the same 
principles of dopamine replacement but has a novel delivery system with a percutaneous 
jejunostomy tube that enables continuous dosing of the medication. There are additional 
novel delivery systems currently being tested including an inhaled levodopa (LeWitt et 
al., 2016) as well as a subcutaneous levodopa (ClinicalTrials.gov).  These have great 
potential to improve the dyskinesias and motor fluctuations that occur with the narrowing 
of the therapeutic window, but it is the same medication that was identified more than 55 
years ago and is not disease modifying. There are several other symptomatic therapies in 
regular use. Dopamine agonists improve PD symptoms, though they are generally not as 
effective as carbidopa/levodopa. Currently available agonists include pramipexole, 
ropinirole and the more recently available transdermal formulation rotigotine.  These 
medications have a place in management, often as monotherapy or even first-line therapy 
among younger patients and/or to help with the motor fluctuations that occur with 
carbidopa/levodopa dosing. However, these medications also have unacceptable side 
effects—about 17% of patients taking dopamine agonists develop compulsive behaviors 
including compulsive gambling, sex, or shopping (Weintraub et al., 2010).  Monoamine 
oxidase inhibitors, rasagiline and selegeline and the recently FDA approved safinamide, 
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may also be useful to augment levodopa. COMT inhibitors, namely entacapone and 
tolcopone, also seek to extend the life of levodopa. Finally, amantadine is useful for 
treatment of dyskinesias and is sometimes used for symptomatic treatment (Dietrichs & 
Odin, 2017).  
There are also surgical options currently available for PD symptomatic treatment. 
These surgical treatments are most effective at improving the motor fluctuations due to 
the narrowing therapeutic window of levodopa and the pharmacokinetics of medication 
administration.  The most frequently performed surgical procedure for PD is deep brain 
stimulation (DBS) that involves placing electrodes in either the globus pallidus internus 
or the subthalamic nuclei.  The resulting constant stimulation attenuates the motor 
fluctuations that occur later in the PD course. Prior to the proven effectiveness of DBS, 
ablative procedures were common. The pallidotomies and thalamatomies were helpful for 
symptomatic treatment but concerns over side effects and the irreversibility led to DBS 
becoming more common (Fasano, Daniele, & Albanese, 2012). New approaches to 
ablative procedures are being explored and such an approach continues to have potential 
benefit for PD patients. Carbidopa/levodopa intestinal gel (marketed as Duopa in the US) 
is a newer surgical approach mentioned previously that involves placement of a 
percutaneous jejunostomy tube and the subsequent infusion of carbidopa/levodopa 
intestinal gel.  
Non-pharmacological treatments for PD have also been shown to benefit 
symptoms. Exercise has been proven to be critical to the treatment of the motor 
symptoms of PD (Goodwin, Richards, Taylor, Taylor, & Campbell, 2008).  Specific 
exercises that have shown benefit include tai chi (F. Li et al., 2012) and a special type of 
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physical therapy called the LSVT BIG program (Ebersbach et al., 2015). Many patients 
also benefit from other forms of physical therapy, speech therapy, and occupational 
therapy (Sturkenboom et al., 2013) that provide tailored exercises and adaptive 
mechanisms to improve their health and function. 
Treatment of non-motor symptoms of PD 
The treatment of the non-motor symptoms of PD, similar to the treatment of the 
motor symptoms, aims to ameliorate the functional impact of changes. One of the most 
common and debilitating non-motor symptoms of PD are the cognitive changes. Again, 
there are no disease modifying therapies for the cognitive changes though there is some 
evidence that exercise may improve cognition (David, FB et al., Mov Dis 2015). Most 
frequently, clinicians use the medications initially developed for treating Alzheimer’s 
disease (AD). Given the overlap in pathophysiology between AD and PD this is a 
reasonable approach and subsequent trials support use of acetylcholinesterase inhibitors, 
specifically rivastigmine, as good pharmacological choices to treat the cognitive changes 
observe in PD. With these treatments, some patients demonstrate clear improvements 
while still others demonstrate worsening cognition in the setting of these medications  
(Svenningsson, Westman, Ballard, & Aarsland, 2012). Memantine, a partial NMDA-
receptor antagonist, has shown less benefit in cognition in at least one study, with other 
studies demonstrating a mild but not always significant improvement in quality of life 
(Svenningsson et al., 2012).  There is also a fluid interaction between cognition and many 
of the PD motor treatments. Frequently, stopping or decreasing amantadine, any of the 
dopamine agonists, and sometimes even levodopa can lead to cognitive improvement. 
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Conversely, some patients require larger and more optimal doses of levodopa to improve 
their cognition.  
Neuropsychiatric manifestations of PD are also very common and debilitating for 
many of our patients, with depressive symptoms and anxiety affecting at least 40% of 
individuals with PD (Aarsland, Marsh, & Schrag, 2009) and can lead to significant 
disability, with patients reporting that depression is a greater determinant of health-
related quality of life than motor symptoms (Soh, Morris, & McGinley, 2011). 
Furthermore, individuals with PD and depression have greater disability compared to 
those with PD alone (Pontone et al., 2016). Treatment for the depression and anxiety 
related to PD relies primarily on the selective serotonin reuptake inhibitors (SSRIs) and 
selective serotonin and norepinephrine reuptake inhibitors (SNRIs) (Pachana et al., 
2013).  Cognitive behavior therapy has also been shown to have modest benefits 
(Pachana et al., 2013).  For many patients, the anxiety symptoms also correlate with the 
“off” time in their motor fluctuations. For these patients’ adjustment of their dopamine 
schedule can be very beneficial. PD-related psychosis is also common (Aarsland & 
Kramberger, 2015), with treatment relying primarily on quetiapine or clozaril due to the 
prominent extrapyramidal side effects of the other antipsychotics.  In addition, the FDA 
recently approved the novel antipsychotic pimavanserin to treat PD-related psychosis. 
Pimavanserin is a selective serotonin 5-HT2A inverse agonist without dopaminergic, 
adrenergic, histaminergic, or muscarinic affinity, therefore potentially leading to fewer 
side effects (Cummings et al., 2014). Despite these treatment options, the depression, 
anxiety, and psychosis associated with PD remain debilitating for many patients and new 
treatments are needed to ease the burden of these symptoms.  
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Autonomic nervous system changes are also common in later-stage PD 
(Cersosimo & Benarroch, 2012). For individuals with orthostatic hypotension the usual 
treatments are midodrine, fludrocortisone, and droxidopa, the latter of which was FDA 
approved more recently and is specific for treatment of orthostasis in PD. These 
medications act on the adrenergic receptors, inflammatory cytokines, and peripheral 
arterial and venous vasoconstriction (Seppi et al., 2011).  They are also associated with 
supine hypertension, though droxidopa is supposed to have less of an instance of that 
complication. For urinary urgency, frequency, and nocturia, often with accompanying 
bladder spasms, anticholinergics have been found to be reasonably effective though may 
have cognitive side effects and some patients may benefit from botulinum toxin 
injections into the bladder muscle (Giannantoni et al., 2009).    
Pain and fatigue are also common in PD. The pain is often due to the motor 
fluctuations, dyskinesias, off medication times, and central limb pain (Chaudhuri & 
Schapira, 2009), as well as a neuropathy, which is common in PD (Rajabally & Martey, 
2011).  The treatment for many of the pain symptoms is therefore adjustment of their 
levodopa to reduce the fluctuations and total off times, as well as some nighttime 
carbidopa/levodopa to assist with the pain at night (Chaudhuri & Schapira, 2009). 
Gabapentin and other neuropathy treatments are also useful for the neuropathic pain. 
Treatment of the fatigue involves first a comprehensive assessment of the etiology of the 
fatigue including a good sleep history, as well as an assessment of additional contributors 
to fatigue including depression and other medical comorbidities such as pulmonary and 
cardiac function changes. Treatment can then be targeted at the etiology as well as 




Challenges to the identification of biomarkers 
The lack of disease-modifying therapies is due to both the significant work 
required to elucidate the pathophysiology of PD and the significant hurdles translating the 
basic science, pre-clinical and clinical knowledge into effective therapeutics. First and 
foremost, the phenotypic and likely pathophysiologic heterogeneity of the disease means 
that a therapy that is potentially efficacious for one subset of the disease is drowned out 
by its lack of effect on other disease subsets (Lang & Espay, 2018). Importantly, if the 
potential disease modifying therapy had a large effect on some or all PD pathophysiology 
pathways, the heterogeneity of the disease would not be as important for determining the 
efficacy of the therapeutic.  In other words, this heterogeneity is an issue because the 
effect size of the therapeutics tested thus far is either small or nonexistent.  
There are also significant challenges related to study design.  Since PD is a slowly 
progressive disease, study designs must follow patients for enough time for them to 
demonstrate clinical changes. In the absence of a large disease modification or even 
disease reversal of the therapy, we would anticipate patients in both the therapeutic and 
placebo arms to be clinically worse at the end than at the beginning of a trial. We 
therefore need to compare relative differences in disease progression.  Different trial 
designs including a delayed start design have been used to try to overcome this issue, but 
it remains a challenge in all trials. Again, the known heterogeneity of PD and its rate of 
progression will complicate this calculation.  
Finally, clinical trials rise and fall based on the quality of their outcome 
measurements. At this time, the primary motor outcome in every PD study is the Unified 
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Parkinson’s Disease Rating Scale (UPDRS) or the more recent Movement Disorder 
Society-UPDRS (MDS-UPDRS). Both scales rely on patient responses and physician 
assessments to quantify a patient’s non-motor and motor deficits. While there is 
significant literature validating the tool and an online course that administrators of the 
tool need to pass, it remains subjective.  This subjectivity is made even more challenging 
in PD by the motor fluctuations of the disease—patients’ MDS-UPDRS scores may vary 
widely within even an hour of testing. Significant research is ongoing into identification 
of more objective clinical outcomes with the use of wearables and other technologies. 
Biomarkers would therefore make a fundamental difference in identification of a disease 
modifying therapy by allowing for the stratification of PD patients into different 
pathophysiologic categories and would provide objective outcome measurements and 
measures of medication target engagement. 
 
Biomarkers 
A biomarker is “a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic response 
to a therapeutic intervention.” ("Biomarkers and surrogate endpoints: preferred 
definitions and conceptual framework," 2001). A classic example of a disease biomarker 
is fasting blood glucose levels for diabetes mellitus—blood glucose levels diagnose 
diabetes, track disease progression, and monitor response to therapeutics. An ideal 
biomarker for PD would be similar—it would be an objective measurement that allows us 
to diagnose PD, follow disease progression, and monitor response the therapeutics. In 
practice, it is likely that we will need a collection of different compounds for each of 
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these types of biomarkers.  In addition, given the phenotypic heterogeneity of PD, 
different phenotypes of PD may require different markers. A PD biomarker marker may 
be biofluid or biochemical, clinical, genetic, or imaging based. 
 One of the many challenges to biomarker identification is the variability of the 
methodology used to collect and measure the marker. There are many large research 
programs within PD that are seeking to address this challenge through the standardization 
of biofluid acquisition protocols. The Harvard Biomarker Study (HBS), established in 
2008 (Mohammadi, 2013), developed a longitudinal biobank of clinical data with 
associated blood, CSF, RNA, DNA, and ultimately autopsy tissue. Its primary goal is to 
identify biomarkers for PD and other neurodegenerative diseases. The Michael J. Fox’s 
Foundation’s (MJFF) Parkinson’s Progression Markers Initiative (PPMI) began in 2010 
and has enrolled more than 1400 participants as of January 2019 in the many different 
subgroups of the study (PPMI). PPMI seeks to identify progression markers of PD and 
serves as a validation cohort for biomarkers discovered through other research studies, 
including the HBS, and the newer studies BioFIND and the Parkinson’s Disease 
Biomarker Program (PDBP) (Rosenthal et al., 2016). The BioFIND study, funded by the 
MJFF and the National Institute of Neurological Diseases and Stroke (NINDS), enrolled 
individuals with moderate stage PD in a cross sectional, case control study and included 
blood and CSF collection. The PDBP, also NINDS funded, is a longitudinal biofluid 
collection from individuals with all stages of PD and controls as well as some atypical 
parkinsonism patients. Biofluids from each of these investigations are submitted to a 
central repository and are being used by researchers at numerous institutions to discover 
and validate new biomarkers. 
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A detailed review of all assessed biomarkers is beyond the scope of this 
manuscript and readers are referred to other articles discussing biomarkers including 
Gwinn et al (Gwinn et al., 2017) and Chen-Plotkin et al (Chen-Plotkin et al., 2018). We 
will discuss a few of the more promising protein and biofluid-based biomarkers, as these 
are the potential targets for new therapeutics. The most frequently tested biofluid 
biomarker in PD is alpha-synuclein, the pathological protein associated with neuronal cell 
loss in PD. Total alpha-synuclein levels have been found to be lower in the CSF of 
individuals with PD (Mollenhauer, El-Agnaf, Marcus, Trenkwalder, & Schlossmacher, 
2010) though levels do not seem to change with increasing disease severity. Pathological 
tissue concentration of alpha-synuclein also seems to separate individuals with PD 
compared to controls. Gastric (Sanchez-Ferro et al., 2015), rectal and colonic (Pouclet et 
al., 2012) biopsies demonstrated significant concentration of  alpha-synuclein in the 
tissue of individuals with PD compared to controls. Alpha-synuclein has also been found 
in the skin (Zange, Noack, Hahn, Stenzel, & Lipp, 2015) and peripheral autonomic nerve 
fibers that innervate the heart (Iwanaga et al., 1999), abdominopelvic organs (Minguez-
Castellanos et al., 2007) and the paraspinal sympathetic ganglia and endocrine organs 
(Beach et al., 2010). In addition, presence of posttranslationally modified alpha-synuclein 
(p-serine-129) in the CSF (Y. Wang et al., 2012) and skin nerve fibers differentiates 
between PD and MSA (Zange et al., 2015).  Another promising marker for PD is the DJ-
1 protein. DJ-1 likely has many roles including inhibiting alpha-synuclein aggregation. 
Total DJ-1 levels are lower in the CSF of individuals with PD (Hong et al., 2010) and 
higher total DJ-1 levels were found to correlate with greater disease severity in the saliva 
of PD patients (Masters, Noyce, Warner, Giovannoni, & Proctor, 2015). However, total 
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DJ-1 levels in the plasma are not significantly different between those with PD and those 
with Alzheimer’s disease or controls (Shi et al., 2010), limiting DJ-1’s utility as a 
biomarker. Seven DJ-1 post-translationally modified isoforms in the whole blood may be 
biomarker candidates and further research is forthcoming.  Both alpha-synuclein and DJ-
1 are also part of protein panels that, when looked at together, had reasonable sensitivity 
(> 92%) and specificity (up to 60%) for both PD vs controls and PD vs some of the 
atypical parkinsonisms (sensitivity about 99% and specificity about 90%) (Shi et al., 
2011).  Other potential markers of PD diagnosis or motor progression include ApoA1 
((Qiang et al., 2013); (Swanson et al., 2015)), Vitamin D (Ding et al., 2013) and urate 
levels (Ascherio et al., 2009), though none of these markers have held up under 
significant further scrutiny. 
Biochemical markers for PD-dementia include the most common markers for both 
PD and Alzheimer’s disease, specifically amyloid beta, tau and phospho-tau. Lower total 
alpha-synuclein levels predicted preservation of cognitive function in PD (Stewart et al., 
2014). Furthermore, up to one half of individuals with PD-dementia had the biomarker 
signature of Alzheimer’s disease with amyloid-beta42 levels reduced (Montine et al., 
2010). Still others have noted that a combination of CSF amyloid beta42 as well as age, 
REM behavior symptomatology, smell testing, and striatal uptake on DaTScan imaging 
predicted dementia within two years (Schrag, Siddiqui, Anastasiou, Weintraub, & Schott, 
2017). While there are CSF-based markers for vascular injury including most 
prominently e-selectin and vascular cell adhesion molecule-1 (VCAM-1) (G. Li et al., 




There are many other markers that are undergoing testing and validation in new 
cohorts. Importantly, none of the markers that we have discussed nor any of these new 
markers are ready to be used in standard clinical care.  
Aberrant proteostasis  
 The presence of Lewy bodies, intraneuronal and cellular proteinaceous inclusions 
that are sometimes enriched with ubiquitin, in afflicted regions of the PD brain provides 
glaring evidence of abnormal protein processing and leads to accumulation of mutant, 
misfolded or damaged intracellular proteins. Notably, α-synuclein that is prone to form 
amyloid-like aggregates is a major constituent of Lewy bodies and Lewy neurites in 
sporadic and inherited PD. Consequently, the aggregation potential of α-synuclein has 
gained much attention as a possible molecular cause underlying most forms of PD. 
Supporting this notion are observations that familial PD associated SNCA point 
mutations, namely A53T, A30P, E46K, and H50Q all increase the propensity of α-
synuclein to aggregate in vitro (Narhi et al., 1999); (J. Li, Uversky, & Fink, 2001); 
(Khalaf et al., 2014). SNCA triplications also facilitate the aggregation process, likely as 
a result of increased protein load and consequent macromolecular crowding (Miller et al., 
2004) . Truncated, aggregation prone forms and oligomer forming variants of α-synuclein 
promote dopaminergic neurotoxicity in vivo implicating the aggregated species in 
pathogenesis (Periquet, Fulga, Myllykangas, Schlossmacher, & Feany, 2007); (Winner et 
al., 2011). Furthermore, a number of factors presumed to play a contributing role in 
sporadic PD including oxidative and nitrosative stress accelerate α-synuclein misfolding. 
Nevertheless, the presence of aggregated α-synuclein by and of itself does not prove if 
protein misfolding and aggregation exhibit a causal relationship with neuronal death or 
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represent a secondary step in the course of the disease. In fact, while overexpression of 
wild-type or mutant α-synuclein produces neurological defects in mice and rats, none of 
these models recapitulate the entire spectrum of PD phenotypes. Furthermore, Lewy 
bodies are not common to all genetic forms of PD. While mutations in GBA are 
associated with Lewy bodies and most cases of LRRK2 have α-synuclein inclusions, 
some LRRK2 mutations are devoid of Lewy pathology. For as many cases of parkin with 
α-synuclein inclusions, an equal number without Lewy pathology have been reported. 
Accumulating evidence indicates that α-synuclein oligomers can themselves have 
detrimental effects on various physiological functions that culminate in neurotoxicity. 
While the underlying mechanisms of aggregate toxicity are poorly understood, one 
possibility is that α-synuclein aggregates composed of more heterogeneous oligomers 
may expose flexible hydrophobic surfaces that promote aberrant interactions with other 
cellular proteins resulting in their sequestration and functional impairment (Campioni et 
al., 2010); (Bolognesi et al., 2010). Such inhibition of central protein quality control and 
clearance mechanisms can lead to further propagation of folding defects and set forth 
feed-forward mechanisms of further neuronal injury. Oligomeric intermediates of α-
synuclein can also compromise the integrity of various membrane structures in the cell 
and cause neurotoxicity through pore-like membrane permeabilization (Kayed et al., 
2004) or by destabilization of the membrane allowing nonspecific ion-transport (Danzer 
et al., 2007). Thus, disruptions in basic cellular functions that interface with the unique 
biology of dopaminergic neurons could result in multifactorial toxicity with prolonged 
periods of such alterations eventually causing neuronal death.   
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 How α-synuclein aggregation associated proteotoxicity dominates clearance 
mechanisms and impinges on neuronal survival is an important question to explore, 
particularly when not one but three protein quality control pathways, namely ubiquitin 
proteasome system (UPS), chaperone-mediated autophagy (CMA) and macroautophagy 
are involved in regulating α-synuclein levels. Monomeric α-synuclein is actively 
degraded by all of these pathways that also compensate each other to maintain steady-
state levels of α-synuclein  (Kaushik, Massey, Mizushima, & Cuervo, 2008); (Koga, 
Martinez-Vicente, Macian, Verkhusha, & Cuervo, 2011); (Massey, Kaushik, Sovak, 
Kiffin, & Cuervo, 2006)). However, oligomers and aggregates are primarily degraded via 
macroautophagy. Overexpression of wildtype α-synuclein also impairs macroautophagy 
by inhibiting autophagosome biogenesis in a Rab1a dependent manner (Winslow et al., 
2010). Such reduction in autophagy, a major route for clearance of aggregation-prone 
intracytoplasmic proteins could subsequently increase the cellular concentration of such 
proteins thereby augmenting their probability of aggregation. In fact, α-synuclein induces 
fibrillation of tau, which then promotes synergistic fibrillation of both proteins (Giasson 
et al., 2003) indicating that increased α-synuclein load could serve as a template and 
initiate feed-forward cycles of indiscriminate aggregate formation. (Tau, of course, is one 
of the pathologic proteins found in AD, thus demonstrating a pathologic link between the 
two diseases and explaining some of the reason for the prominence of AD pathology 
among individuals with PD (Irwin et al., 2013)). Given the prominent role 
macroautophagy plays in the clearance of dysfunctional mitochondria (a process referred 
to as mitophagy) (reviewed in (Ryan, Hoek, Fon, & Wade-Martins, 2015)), α-synuclein 
mediated inhibition of macroautophagy could have far reaching effects on mitochondrial 
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quality control and increase neuronal susceptibility to proapoptotic insults, all of which 
are implicated as pathogenic processes in PD.  
  Post-translational modifications of PD linked proteins also appear to impact its 
autophagic clearance. In the case of α-synuclein, PLK2 kinase mediated phosphorylation 
of α-synuclein at (S129) facilitates its autophagic clearance (Inglis et al., 2009); 
(Oueslati, Schneider, Aebischer, & Lashuel, 2013)) while phosphorylation of α-synuclein 
at tyrosine 39 (Y39) by the tyrosine kinase, c-Abl increases its propensity to aggregate  
(Mahul-Mellier et al., 2014); (Brahmachari et al., 2016). Of note, phospho-Y39 α-
synuclein accumulation is observed in substrantia nigra and striatum in postmortem PD 
brains as well as in Lewy bodies of PD patients. Moreover, c-Abl overexpression in wild 
type mice leads to dopamine neuron degeneration with concomitant elevation of 
phospho-Y39 α-synuclein and pathogenic α-synuclein accumulation. While c-Abl 
overexpression accelerates behavioral abnormalities and pathology of human A53T 
transgenic mice, these defects are ameliorated by c-Abl knockout, indicative of the 
pathogenic contribution of c-Abl to α-synuclein neurodegeneration (Brahmachari et al., 
2016). Various oxidative, nitrosative and dopaminergic stressors implicated in PD are 
known to activate c-Abl (Sun et al., 2000); (Ko et al., 2010); (Imam et al., 2011)) and 
could in part explain the nigrostriatal neuronal injury and pathogenic process underlying 
sporadic forms of PD. These studies indicate that selective inhibition of c-Abl could be 
neuroprotective. Indeed, the brain penetrant c-Abl inhibitor nilotinib ameliorates striatal 
motor deficits in a MPTP mouse model of PD (Tanabe et al., 2014) and dopamine neuron 
loss in a viral mouse model of α-synuclein toxicity (Hebron, Lonskaya, & Moussa, 2013) 
and human studies of nilotinib are ongoing as described below. Early neuroinflammatory 
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responses to α-synuclein also appear to be modulated by c-Abl inhibitors (Hebron et al., 
2014). A major caveat to be considered with these studies is that the inhibitors used are 
non-specific kinase inhibitors with broad activity profiles towards a wide range of kinases 
and are thus likely to have unforeseen side effects with substantial toxicity. The presence 
of markers of c-Abl activation like phospho-Y39 α-synuclein in the PD brain 
nevertheless, provide a rationale for developing specific c-Abl inhibitors with better 
safety records. By preventing α-synuclein Y39 phosphorylation and its propensity to 
aggregate, therapeutics based on c-Abl inhibition could promote synuclein clearance and 
thereby counteract toxicity associated with synucleinopathies.  In a parallel pathway, 
stress-induced activation of c-Abl also has an inhibitory effect on the multifunctional E3 
ligase parkin (Ko et al., 2010); (Imam et al., 2011), mutations in which are the most 
common cause of autosomal recessive PD (Khan et al., 2003). Tyrosine phosphorylation 
of parkin by c-Abl inactivates a catalytic function of parkin resulting in toxic 
accumulation of parkin substrates like aminoacyl-tRNA synthetase-interacting 
multifunctional protein type 2 (AIMP2) (Y. Lee et al., 2013), fuse-binding protein 1 
(FBP1) (Ko, Kim, Sriram, Dawson, & Dawson, 2006); (Ko et al., 2010)) and PARIS 
(Parkin Interacting Substrate) (Shin et al., 2011)) that cause dopaminergic 
neurodegeneration. Of note, PARIS and AIMP2 accumulate in familial PD with parkin 
mutations, sporadic PD, conditional parkin knockout mice and MPTP intoxicated mice 
and are thus pathologically relevant parkin substrates (Y. Lee et al., 2013); (Shin et al., 
2011)). Thus, modifying the phosphorylation status of parkin by interfering with c-Abl 
activation provides unique opportunities to maintain parkin in a catalytically active state.  
In this regard, c-Abl inhibitors Imatinib, INNO-406 have an effect towards reducing 
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tyrosine phosphorylation of parkin and suppressing upregulation of parkin substrates like 
FBP1 and AIMP2 thereby slowing the progression of PD (Imam et al., 2011); (Ko et al., 
2010); (Imam et al., 2013). Other c-Abl inhibitors like Nilotinib reduce c-Abl activation 
and levels of PARIS in a MPTP-induced model of PD (Karuppagounder et al., 2014).  In 
other words, blocking or stopping c-Abl activation has significant impact on a number of 
pathways that together may slow the progression of PD.  Nilotinib, imatinib, and other c-
Abl inhibitors are already FDA approved for the treatment of acute lymphocytic leukemia 
and other disorders with Philadelphia chromosome translocations. Given their potentially 
promising mechanism of action, studies are currently underway to test the c-Abl 
inhibitors in PD patients. A small, open labeled study of nilotinib in PD showed both a 
reasonable clinical response and a reduction in α-synuclein levels in the CSF (Pagan et 
al., 2016).  The pilot data also indicated that nilotinib had the potential to be safe in this 
population. There are now two randomized controlled trials of nilotinib vs placebo in PD 
patients to determine the safety and potential efficacy of this medication. One study seeks 
to enroll 75 individuals at a single site and is currently enrolling. The other study is also 
underway and is a collaboration of the Michael J. Fox Foundation, the Van Andel 
Research Institute, and the Cure Parkinson’s Trust (ClinicalTrials.gov). In addition, as 
discussed above, development of more targeted c-Abl inhibitors would facilitate further 
explorations as to the utility of this pathway as potential disease-modifying therapy in 
PD.  
 Other components of the c-Abl pathway also provide potential therapeutic targets. 
The elevation of AIMP2 activates poly-ADP-ribose polymerase 1 (PARP1), leading to an 
increase in the poly-ADP-ribose (PAR) polymer.  This activation of PARP1 and 
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subsequently PAR, leads to the accumulation of significantly more toxic alpha-synuclein 
oligomers. Moreover, PARP1 inhibitors stopped the accumulation of this toxic alpha-
synuclein in a mouse PD model (Kam et al., 2018).  PARP1 inhibitors are also FDA 
approved treatments for a variety of gynecological cancers and are undergoing testing for 
other cancers as well. Furthermore, if markers of c-Abl activation for instance, Y245 of 
c-Abl, Y39 of α-synuclein, Y143 of parkin, and PAR levels are detectable in biological 
fluids like the CSF of PD patients, they could be utilized as biomarkers of disease 
progression as well as to monitor the efficacy of c-Abl inhibition and PARP1 inhibition-




Intercellular transmissibility of α-Synuclein 
Accumulating evidence indicates that many neurodegenerative diseases involve 
cell-to-cell spreading of disease related proteins that form the hallmark lesions in their 
respective neurodegenerative disorders (Guo & Lee, 2014). While such lesions were 
initially thought to arise in a cell-autonomous manner and confined to selectively 
vulnerable brain regions, the notion that a prion-like mechanism could underlie the 
intercellular transmissibility of such proteins is gaining momentum. This hypothesis also 
fits nicely with the Braak model of PD progression (Braak et al., 2003). In the Braak 
model, abnormal α-synuclein forms Lewy bodies in specific, susceptible neuronal types, 
beginning in the peripheral and enteric nervous system and moving caudally through the 
brainstem, midbrain, and then eventually the cortex. Indeed, neuropathological 
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examination of α-synuclein aggregates in postmortem PD brain tissues indicate the 
presence of Lewy bodies in several other regions of the brain apart from the nigra 
(Surmeier & Sulzer, 2013), implying that the pathogenic changes spread within the brain 
as the disease progresses, affecting multiple functional networks. Several recent studies 
have implicated the cell-to-cell spread of α-synuclein likely via the extracellular milieu as 
a potential mechanism underlying such a pathological progression. This spread of the 
pathologic protein may go between vulnerable cell populations or between loci that are 
connected as part of the neuronal circuitry. Consistent with the impairment of multiple 
neural circuitry during the disease process, PD patients describe constipation and REM 
behavioral disorder that predate their motor symptoms and localize to the brainstem. 
Following onset of motor symptoms due to substantia nigra involvement, patients may 
subsequently develop cognitive impairment in association with cortical involvement 
(Jankovic, 2008). 
Even though α-synuclein is abundant in neuronal cytoplasm, a small amount of α-
synuclein is, for unknown reasons, constitutively released from neuronal cells. In 
humans, nanomolar concentrations of α-synuclein is detected in the blood plasma, brain 
interstitial fluid and CSF (El-Agnaf et al., 2003); (El-Agnaf et al., 2006). A fraction of 
cellular α-synuclein is partitioned into cytosolic vesicles and secreted through an 
unconventional exocytic pathway even from healthy mammalian cells and primary 
neurons in culture (H. J. Lee, Patel, & Lee, 2005). Intriguingly, α-synuclein secretion is 
increased under various stress conditions including proteasomal, mitochondrial, 
lysosomal dysfunctions and oxidative stress (Jang et al., 2010); (H. J. Lee et al., 2011); 
(H. J. Lee et al., 2013). Under such conditions, vesicular translocation of α-synuclein is 
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also increased and vesicular α-synuclein appears to be more prone to aggregation than 
cytosolic α-synuclein (Jang et al., 2010); (H. J. Lee et al., 2005). Consequently, much of 
the α-synuclein secreted from cells under stress conditions is in oligomeric forms.  
Recent work also demonstrates that aspects of α-synuclein transmission and 
aggregation can be recapitulated in murine model systems by exogenous introduction of 
pathological α-synuclein derived from diseased tissues or in vitro generated preformed 
fibrils (PFFs) of α-synuclein (Luk et al., 2012); (Volpicelli-Daley et al., 2011); 
(Osterberg et al., 2015); (Jones et al., 2015). The presence of miniscule quantities of 
aggregated or fibrillar α-synuclein in these scenarios has been demonstrated to serve as 
nucleation sites that seed the aggregation of endogenous α-synuclein, and this 
aggregation spreads along synaptically connected pathways likely through sequential 
events of exocytosis and endocytosis, reminiscent of a prion-like mechanism. Moreover, 
embryonic mesencephalic neurons grafted into the neostriatum of PD patients also 
develop α-synuclein positive Lewy bodies and Lewy neurites that are associated with 
functional decline of the grafted dopaminergic neurons (Kordower, Chu, Hauser, 
Freeman, & Olanow, 2008); (Kordower, Chu, Hauser, Olanow, & Freeman, 2008); 
(Hely, Reid, Adena, Halliday, & Morris, 2008), indicating that cell-cell propagation and 
misfolding of α-synuclein could underlie the CNS spread of Lewy bodies and Lewy 
neurites.  
The emergence of α-synuclein transmission hypothesis has provided a viable 
explanation for the stereotypical spreading of neuropathology and progressive 
deterioration of multiple functional networks in PD. However, there are still a number of 
open-ended questions that should be carefully considered to be able to evaluate the 
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applicability of a prion-like mechanism to the underlying disease process. One of the 
more elusive challenges for this transmission hypothesis is to define the seed. In PD 
research, the presence of α-synuclein containing seed has been empirically defined by 
showing that extracts from pathogenic tissues or pre-aggregated forms of in vitro 
generated α-synuclein catalyze aggregate formation (Golde, Borchelt, Giasson, & Lewis, 
2013). However, in vitro generated variants of synthetic α-synuclein fibrils may not 
necessarily be identical to fibrils formed in the human brain which limits the 
establishment of a convincing link between aggregate forms with ‘seeding’ potential and 
disease pathogenesis. A recent study reported the existence of two different 
morphologically distinct oligomeric α-synuclein aggregates in post-mortem PD brain 
tissues (Xin et al., 2015). Distinct α-synuclein strains that differ in their conformation and 
activity have also been observed to differ in their propensity to cross-seed tau aggregation 
(Guo et al., 2013), implying that conformational variants of α-synuclein can possess 
varied biological activities and thus, tremendous heterogeneity likely underlie 
synucleinopathies. Future studies should therefore be aimed at isolating the pathogenic 
protein species originating from the diseased brain to identify the pathogenic species of 
α-synuclein. In this regard, protein misfolding cyclic amplification (PMCA), a 
biochemical diagnostic procedure was recently demonstrated to be highly sensitive in its 
detection of α-synuclein oligomers in biological fluids of PD patients (Shahnawaz et al., 
2017). Intriguingly, PMCA has been employed for detection of prions in biological fluids  
(Saborio, Permanne, & Soto, 2001); (Saa, Castilla, & Soto, 2006) and has also  been used 
to gain mechanistic understanding of factors involved in prion transmission (Morales, 
Duran-Aniotz, Diaz-Espinoza, Camacho, & Soto, 2012). Seeding competent β-amyloid 
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oligomers have also been detected with high precision in the CSF of AD patients using 
PMCA (Salvadores, Shahnawaz, Scarpini, Tagliavini, & Soto, 2014). The PMCA 
platform adapted for detection of α-synuclein appears to be rather specific in its detection 
(Shahnawaz et al., 2017) which raises the possibility that techniques like these could 
facilitate identification of the pathogenic α-synuclein species that could then be subjected 
to detailed biochemical and biophysical analyses to characterize their transmission 
properties. Notably, the feasibility of detecting α-synuclein in PD biological fluids 
highlights the utility of diagnostic procedures like PMCA in monitoring disease 
progression as well as facilitate preclinical identification of patients likely to develop PD.  
Studies of the transmissible property of α-synuclein have important therapeutic 
implications. Cell-based replacement therapies to replace degenerating dopamine neurons 
are emerging strategies to restore dopamine delivery and abate the debilitating symptoms 
in PD. However, findings from the transmission studies indicate that these approaches 
when used alone may not be successful as the implanted tissues eventually develop Lewy 
pathology owing to synuclein transmission from host tissues. The prevalence of 
extracellular α-synuclein raises the possibility that strategies that promote enhanced 
clearance of extracellular α-synuclein could be beneficial. In fact, the neuroprotective 
effects observed with α-synuclein immunotherapy (J. S. Lee & Lee, 2016) suggest that 
this would be a viable option to curb the intercellular transmission of α-synuclein and 
numerous alpha-synuclein vaccine studies are underway, though none have reported their 
safety and efficacy at this time. However, careful consideration is required to determine if 
diverse pathological strains of α-synuclein exist which would necessitate extensive 
screening for antibodies with higher binding affinity and specificity for distinct 
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pathogenic strains. In this regard, broader applicability can be achieved with antibodies 
that recognize shared conformations of multiple strains, especially those with cross-
seeding potential (Guo & Lee, 2014). Studies on Aβ passive immunotherapy show that 
only 0.1% of circulating antibodies manage to cross the blood-brain barrier (BBB) and 
reach the brain (Yu & Watts, 2013). Therefore, considerable efforts should be directed at 
devising strategies that promote uptake of antibodies across the BBB to maximize 
therapeutic effects.  
 
Additional environmental contributors to disease progression 
Dietary factors and toxin exposures are also associated with modulating disease 
progression. There has been significant evidence showing that higher caffeine intake is 
associated with decreased risk of PD development (Hamza et al., 2011; Popat et al., 
2011) and that caffeine intake helps individuals with their PD symptoms, likely due to the 
caffeine targeting the adenosine receptor. Elevated Vitamin D levels have also been 
found to be associated with PD development and a number of lines of research support 
these findings. Researchers have found that 1) there is an increased expression of the 
Vitamin D Receptor gene among individuals with PD (Scherzer et al., 2007), 2) 25-
hydroxy Vitamin D3 reduces 6-hydroxydopamine induced neurotoxicity (J. Y. Wang et 
al., 2001), and 3) there are lower levels of total Vitamin D and Vitamin D metabolites 
among individuals with PD (Ding et al., 2013).  Total Vitamin D is a combination of 25-
hydroxy-vitamin D2 (25[OH]D2) and 25-hydroxy-vitamin D3 (25[OH]D3).  While 
Vitamin D2 is obtained from exogenous sources, most frequently in the U.S. from 
fortified milk and cereal, Vitamin D3 is endogenous and obtained from conversion of 
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cholesterol in the skin following sun exposure. Vitamin D3 levels are thought to be the 
primary driver of the negative association between Vitamin D levels and PD development 
and severity, further underscoring the importance of sun exposure among individuals 
with PD and/or Vitamin D supplementation (Ding et al., 2013).  
Nicotine may also change PD risk with some research suggesting that nicotine use 
is protective (Ma, Liu, Neumann, & Gao, 2017). To that end, there is an ongoing study of 
transdermal nicotine patch as a disease modifying therapy in PD (ClinicalTrials.gov) to 
determine if individuals who are randomized to receive the nicotine patch will have 
slower disease progression. Alternatively, others postulate that individuals who are in the 
prodromal phase of PD and are going to go on to develop PD are more risk averse or 
maybe even less sensitive to tobacco’s effects, therefore making them less likely to 
smoke (or be able to quit easier) (Ritz, Lee, Lassen, & Arah, 2014). Overall, given the 
well-proven risks of smoking tobacco, cigarette smoking is not a good method of PD 
disease prevention.  
There are other exposures that have been shown to be toxic and accelerate disease 
development. One of the more clinically important toxins is Agent Orange (2,4-
dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) along 
with contaminant 2,3,7,8-TCDD). Agent Orange was used extensively by US forces 
during the Vietnam War as part of a wider crop destruction efforts believed to benefit US 
war goals. Agent Orange exposure has subsequently been linked to the development of 
numerous diseases, including likely increased risk of PD. One large multicenter case-
control study found a more than 2 fold increased odds of PD among those exposed to 
Agent Orange (Tanner et al., 2009) but other studies found no association (Kamel et al., 
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2007). The exact mechanism of neurotoxicity of the chemicals in Agent Orange has not 
been worked out in great detail but it is believed that 2,4-D inhibits microtubule assembly 
and TCDD may increase oxidative stress. Importantly for patient the Veterans 
Administration lists PD on the list of diseases due to Agent Orange exposure and 
therefore patients are eligible for increased VA benefits. 
There are numerous other toxins that have been shown to be associated with PD 
including MPTP, paraquat, and rotenone.  Polychlorinated biphenyls used as lubricants 
and coolants have also been associated with PD as has specific solvents. Please refer to 
the review by Goldman (2014) for further discussion of environmental exposures 
contributing to PD (Goldman, 2014). 
 
Conclusion 
 While described by James Parkinson’s as a single disease, PD and the dementia 
that often develops in conjunction with the disease, is a clinically and 
pathophysiologically variable disease. Bridging the connection between the underlying 
pathophysiology and the clinical heterogeneity is a necessary next step toward the 
development of disease modifying therapies. Biomarkers will help us toward this goal by 
informing clinical trials but identification of better biomarkers will also be informed by 
our growing understanding of the different disease mechanisms. Aberrant α-synuclein is 
emerging as a common endpoint to a number of different diseases pathophysiologies and 
the inciting factor toward others, including inflammatory pathways and increased stress 
on the neuron. The c-Abl pathway may be of particular importance due to its role in both 
sporadic and genetic PD and possible PDD and due to the large number of c-Abl and 
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PARP1 inhibitors that are both FDA approved and in development. Finally, genetic and 
environmental influences overlay and contribute to all of the pathophysiologic changes in 
ways that we are still investigating.  
 The profound pathophysiologic heterogeneity is reflected in the phenotypic 
heterogeneity of the disease. Our patients have variable symptoms ranging from 
bothersome tremors to severe rigidity to significant changes in balance to profound and 
relatively rapid cognitive impairment versus only a mild executive dysfunction.  
Determining the degree to which these different phenotypes are reflective of specific 
underlying pathophysiologies is unknown and would be incredibly instructive toward 
disease modifying therapies. The next two chapters will work toward this goal by first, 
determining if PAR levels in the CSF are related to motor or cognitive decline in PD and 








































A biomarker for Parkinson’s disease (PD) cognitive progression is urgently 
needed to support the development of disease modifying therapeutics. The dementia that 
develops in patients with PD is a devastating and common non-motor symptom of PD, 
with more than 80% of individuals developing PD-dementia (PDD) by 15 years after 
diagnosis (Aarsland et al., 2003). Individuals with PDD have significantly greater 
morbidity and mortality than those with PD alone. Current therapeutic options for both 
PD and PDD have limited efficacy and do not change disease course.  An ideal biomarker 
is part of the pathophysiology of PD, thus confirming its relevance, and has known 
therapeutics that block its pathologic activity.   
The parthanatos cell death pathway is a regulated cell death mechanism that has 
been implicated as a critical pathway in PD pathophysiology (Kam et al., 2018; Y. Lee et 
al., 2013). The pathway likely begins with abnormal alpha-synuclein strains entering the 
neuron, which in turn leads to both a direct and indirect activation of PARP1. This double 
activation of PARP1 leads to an increase in PAR, which subsequently results in DNA 
fragmentation and dopamine neuron cell death (Kam et al., 2018). PARP1 inhibitors are 
currently FDA approved for a number of gynecologic cancers and currently in Phase II 
studies for diseases as diverse as prostate cancer (ClinicalTrials.gov) and stroke 
(ClinicalTrials.gov) and have been considered for testing in PD (Martire, Mosca, & 
d'Erme, 2015; Scott, Dawson, & Dawson, 2017). Furthermore, we have previously shown 
that cerebrospinal fluid (CSF) PAR levels are different between PD and control patients 
in two separate cohorts (Kam et al., 2018).  
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We now further develop the role of PAR as a potential biomarker to look at its 
behavior over time and ability to predict disease change. Specifically, we hypothesize 
that CSF PAR levels 1) continue to separate PD and control participants over time, 2) 
PAR levels at baseline and over time predict cognitive decline, and 3) PAR levels predict 




 This study was approved by the Johns Hopkins Institutional Review Board. We 
utilized clinical data and CSF from the Johns Hopkins site of the NINDS Parkinson’s 
Disease Biomarker Program (PDBP) (Gwinn et al., 2017; Rosenthal et al., 2016). The 
PDBP is a consortium of sites investigating a biomarker for PD, with each site 
completing common assessments but each investigator having control over additional 
data collected and biomarkers investigated. For the JHU PDBP, individuals diagnosed 
with PD and controls were recruited from numerous sources including existing 
longitudinal, observational investigations and the movement disorder clinics at Johns 
Hopkins and affiliated neurologists. Controls were further recruited through asking the 
spouses of PD participants. All PD patients met UK Brain Bank criteria for diagnosis of 
PD and were taking medication to treat the symptoms of PD at the time of enrollment. 
Control participants must have been cognitively normal at the time of enrollment 
(Montreal Cognitive Assessment (MoCA) score of equal to or greater than 26) and did 
not have a first-degree relative with parkinsonism. Efforts were made to ensure that 
control and PD participants were similar in age and education levels, but the control 
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participants were not explicitly age-matched. All participants had to agree to an annual 
lumbar puncture and therefore control and PD participants for whom a lumbar puncture 
could not be safely obtained were excluded from the investigation. We did continue to 
follow individuals who opted out of subsequent lumbar punctures, became ineligible to 
undergo a lumbar puncture due to anticoagulation therapy, and those whose lumbar 
punctures we were unable to obtain.  
Clinical diagnosis was checked at each follow up visit and individuals who no 
longer fit diagnostic criteria for PD were excluded from this analysis (n=2, 1 individual 
was subsequently diagnosed with Progressive Supranuclear Palsy-Parkinson’s subtype 
and 1 individual has concomitant hydrocephalus). Enrollment began in 2012 and was 
completed in 2017 and follow up ended in August of 2018. Between 2012 and August of 
2017, visits were every 6 months and then participants underwent a final annual visit 
during the last year of the investigation. Throughout the study the annual visits 
incorporated detailed assessments of cognition, psychiatric symptomatology, as well as 
motor evaluations and review of medications, smell function, and family history. 
Participants also underwent their annual lumbar puncture in conjunction with this visit as 
well as a blood draw and urine collection. The 6-month visits included review of 
medication and primarily motor testing as well as a blood draw and urine collection. 
Since lumbar punctures and comprehensive cognitive testing were obtained annually, this 
investigation includes solely data obtained at the annual visits.  
 
Outcome variable: Cognitive diagnosis 
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 At each annual visit participants underwent approximately 80 minutes of 
cognitive testing, which included two tests in each of five cognitive domains. Each 
participants’ cognitive testing was normed to age and education standards.  In addition, 
each participant identified a study partner that was willing and able to report on the 
participants cognitive and functional state. This informant underwent a structured 
interview that allowed us to determine a Clinical Dementia Rating (CDR) Scale score. 
This CDR was modified from what is typically used in an Alzheimer’s Disease 
population to account for functional difficulties due to motor impairment such that we 
could focus on any challenges the participant may have due to cognitive impairment. The 
cognitive diagnosis was subsequently based on consensus conference, during which the 
movement disorder physicians, clinical psychologists, nurses and research coordinators in 
attendance at each meeting considered both the testing data and the information obtained 
from the informant to stratify the participant’s cognition into normal, mild cognitive 
impairment, and dementia (Cholerton et al., 2013).  We evaluated PAR levels as a 
predictor for change between strata, as well as a predictor of development of any form of 
cognitive impairment and development of dementia. Participants were considered to have 
converted to MCI or dementia either following consistent stratification to that new level. 
If the conversion to the new strata occurred at their last follow up visit, they were also 
considered to have converted.   
 
Explanatory variables: PAR assay 
 The PAR polymer assay is a sandwich ELISA. Two different clones of 
monoclonal anti- PAR antibody were used, with the first antibody coated on the 96-well 
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microtiter plate and the biotinylated anti- PAR antibody added after the PD patient and 
control patient CSF were added. Following incubation, the color change was detected 
with the HRP-conjugated streptavidin saturated at 50 nM.  
 
Additional variables 
Demographic and disease-specific variables were stratified to improve 
interpretation of results. Education was divided into 5 categories (completed high school, 
some college, completed college, completed post-graduate degree) and race was divided 
into Caucasian and Persons of Color. Levodopa Equivalent Dosing for each participant 
was computed according to Tomlinson et al. (Tomlinson et al., 2010). Disease duration 
was computed as age at visit 1 minus age at diagnosis. Depression symptomatology was 
treated as a continuous variable based on Hamilton Depression Scale score and anxiety 
symptomatology was also treated as a continuous variable based on Hamilton Anxiety 
Scale score.  
 
Statistical analysis 
We first looked for baseline demographic differences in our PD versus control 
participants and between the cognitive strata in our PD participants to inform which 
variables we needed to consider to statistically control for in addition to the variables that 
are part of the known pathophysiology of our biomarker. We further assessed the 
behavior of each of our variables with stem plots and subsequent Q-Q plots, allowing us 
to confirm a normal distribution of our data. Patterns of missingness were evaluated with 
regards to both individuals who were lost to follow up by comparing historical trends in 
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clinical data and the behavior of our cohort. Patterns of missingness were also considered 
for individuals for whom we continued to follow but were unable to obtain CSF PAR 
levels by using student t-tests to evaluate demographic and clinical differences.  
To address question 1: Student t-test were used to compare PAR levels at each 
visit both between PD and controls and between the cognitive strata of our PD cohort. To 
address question 2: To determine whether PAR levels at visit 1 predict cognitive decline, 
we first determined whether PAR levels were different at baseline and follow up visits 
between individuals with PD and normal cognition and those with PD and dementia. We 
subsequently sought to determine whether PAR levels at Visit 1 predicted decline by 
establishing two logistic regressions, each of which controlled for age, gender, race, 
education, cognition at baseline, PD-disease duration, depression and anxiety 
symptomatology and follow up time. A multinomial logistic regression used all three 
cognitive strata as its outcome and a logistic regression used cognitive progression to 
dementia as its outcome. To determine whether PAR levels vary over time consistent 
with changes in cognition, the same logistic regressions were set up with the outcome 
variable being cognitive change and the explanatory variables including both PAR at visit 
1 and PAR levels at each visit. To address question 3: We defined individuals whose 
cognitive status progressed as those whose consensus conference diagnosis was 
consistently one or two steps higher than their baseline (ie for individuals who started as 
PD with normal cognition, cognitive status progressed if the individuals was diagnosed 
with PD-mild cognitive impairment for two visits) or someone who was diagnosed with 
the next step higher on the last research visit. Individuals who were diagnosed with 
dementia at the baseline visit were excluded from this analysis. For both question 2 and 
 
 38 
3, our analysis took into account intra-subject correlations of repeated measures. Stata 14 




Our PD and control participants were well matched with regards to age, race, and 
education levels (Table 1). Our PD patients were more likely to be men and had slightly 
higher depression and anxiety symptomatology.  As expected, the cohorts also differed 
with regards to their PD-based motor symptoms and baseline cognitive status. We also 
compared the characteristics of our PD cohort, stratified by cognitive diagnosis at 
baseline. Individuals who were demented at baseline were more likely to be older, male 
and have a longer disease duration than individuals with MCI or normal cognition (Table 
2).  
Patterns of missingness indicate that those who were lost to follow up were 
clinically more advanced than those who remained in the investigation. There were no 
differences between those for whom CSF PAR values were obtained and those for whom 
we were unable to obtain CSF PAR levels (data in appendix). 
 
Cognitive change 
At baseline, we had 25 individuals with PD-normal cognition, 45 individuals with 
PD-MCI and 15 individuals with PDD. Among the 25 individuals who began with 
normal cognition, 8 of them converted to PD-MCI during the course of the investigation 
and 1 individual converted to PD-MCI and then PDD. Among the 45 individuals who 
 
 39 
began the investigation with PD-MCI, 17 converted to PDD during the course of the 
investigation. Those who converted their cognitive status differed from those who did 
with regards to their age, disease duration, Movement Disorder Society – Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) total scores, baseline Montreal 
Cognitive Assessment (MoCA) scores, and disease duration (p< 0.05).  (Table 3).  
 
Question 1: PAR levels at each visit 
PAR levels at visit 1 were not significantly different between PD and controls 
(PD 109.49 (53.51), Control 88.51(49.42), p=0.06). These levels are different than 
previously published (Kam et al., 2018) due to the exclusion of the two individuals that 
no longer meet UKBB criteria. PAR levels at visit 2-4 were different between PD and 
controls  (Visit 2: PD 148.28 (76.93), Control 103.36 (52.98), p<0.01; Visit 3: PD 132.27 
(76.15), Control 85.33 (52.36), p=0.01; Visit 4: 157.25 (56.98) Control 96.91 (40.13), 
p<0.01)(Figure 2). In addition, levels among our control population remain relatively 
stable between visit 1 and visit 3 and visit 4, whereas PAR levels among our PD 
population increase over that follow up time.  
We also compared PAR levels at each visit between those with PD-normal 
cognition, PD-MCI and PDD. There was a significant difference between PAR levels at 
visit 1 between the cognitive strata (PD-normal cognition PAR levels 132.92 (52.96), 
PD-MCI PAR levels 104.46 (48.17), PDD PAR levels 83.72 (56.78), p=0.01) but no 
difference between PAR levels at the other visits (Visit 2: PD-normal cognition PAR 
levels 155.46 (64.75), PD-MCI PAR levels 132.28 (79.62), PDD PAR levels 170.34 
(79.58), p=0.23; Visit 3: PD-normal cognition PAR levels 143.82 (55.08), PD-MCI PAR 
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levels 125.56 (75.36), PDD PAR levels 146.09 (102.73), p=0.71; Visit 4: PD-normal 
cognition PAR levels 133.57 (28.36), PD-MCI PAR levels 163.81 (56.86), PDD PAR 
levels 168.74 (76.80), p=0.45). If we evaluate PAR levels at each visit with the patients 
stratified according to their baseline cognition, it is again only visit 1 that demonstrates a 
significant relationship (Visit 1, as above; Visit 2: PD-normal cognition PAR levels 
135.86 (52.84), PD-MCI PAR levels 148.45 (85.92), PDD PAR levels 172.53 (84.56), 
p=0.48; Visit 3: PD-normal cognition PAR levels 119.96 (62.34), PD-MCI PAR levels 
144.33 (83.10), PDD PAR levels 77.31 (44.30), p=0.26; Visit 4: PD-normal cognition 
PAR levels 146.13 (26.18), PD-MCI PAR levels 156.96 (65.10), PDD PAR levels 273.18 




Question 2: PAR at Visit 1 as a predictor of cognitive decline 
In a simple multinomial logistic regression, for every 10 units increase in PAR 
levels at Visit 1 there is a 12% (95% CI -21% to -1%) reduction in the odds of a 
diagnosis of dementia compared to normal cognition (p=0.03).  The diagnosis of normal 
cognition to PD-MCI was not significant (1% reduction in odds, 95% CI -8% to +7%, 
p=0.87). Controlling for MoCA levels at visit 1, total levodopa equivalent daily dosing, 
disease duration, age, gender, education, race and depression symptomatology continued 
to demonstrate a significant relationship between increased PAR levels at visit 1 and 
reduction in the odds of the diagnosis of PDD versus normal cognition (for every 10 units 
increase in PAR levels at Visit 1, there is a 29% reduction in the odds of diagnosis to 
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dementia from normal cognition, 95% CI -45% to -7%, p=0.01). Controlling for anxiety, 
eliminated the significance of this relationship (for every 10 units increase in PAR levels 
at Visit 1, there is a 21% reduction in the odds of diagnosis of dementia versus normal 
cognition, 95% CI -39% – 3%, p=0.08).  
When taking into account PAR levels at each visit (instead of just Visit 1, as 
above), the relationship between PAR concentration and cognition was similar once we 
controlled for our independent variables but different at the simple multinomial logistic 
regression level. That is, in a simple multinomial logistic regression, for every 10 units 
increase in PAR levels there is a not significant reduction in the odds of a diagnosis of 
dementia compared to normal cognition (OR < 1%, p=0.94, 95% CI -5% to + 5%).  The 
diagnosis of normal cognition to PD-MCI was also not significant (4% reduction in odds, 
95% CI -8% to +1%, p=0.16). Controlling for MoCA levels at visit 1, total levodopa 
equivalent daily dosing, disease duration, age, gender, education, race and depression 
symptomatology continued to demonstrate a significant relationship between increased 
PAR levels and reduction in the odds of the diagnosis of PDD versus normal cognition 
(for every 10 units increase in PAR levels, there is a 29% reduction in the odds of 
diagnosis of dementia versus normal cognition, 95% CI -45% to  -7%, p=0.01). 
Additionally controlling for anxiety, eliminated the significance of this relationship (for 
every 10 units increase in PAR levels, there is a 21% reduction in the odds of diagnosis 
of dementia versus normal cognition, 95% CI -37% to  +2%, p=0.08).   
 
Question 3: PAR as a predictor of cognitive change 
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We subsequently evaluated whether PAR levels were associated with change in 
cognition from PD-normal to PD-MCI or PD-MCI to PDD. In both the simple logistic 
regression and when controlling for the same dependent variables as above, PAR levels at 
Visit 1 and PAR levels throughout our follow up time did not significantly correlate with 
change of cognition status. See Table 4 for complete model.  
 
Conclusion 
  To our knowledge this is the first investigation that tests c-Abl pathway molecules 
in the  CSF to determine if they predict cognitive decline. We have provided evidence 
that PAR levels separate individuals with PD from controls at most visits after Visit 1, 
but only separate individuals within different cognitive strata at Visit 1. PAR at Visit 1 
may predict a diagnosis of PDD both before and after controlling for a number of 
variables but PAR levels do not predict change in cognitive status from PD-normal 
cognition to PD-MCI or PDD.  
There is significant preclinical data that highlights the importance of PAR in the 
pathophysiology of PD as reviewed in Chapter 1. Briefly, poly ADP ribose synthetase 
activity has been implicated as an important player in DNA damage as early as 1995 
(Zhang, Pieper, & Snyder, 1995). Subsequently, significant investigation has 
demonstrated the importance of PAR and PARP1 in oxidative stress (Virag, 2005), 
progressive neurodegeneration (Hanai et al., 2004), and in the MPTP-based PD model 
(Mandir et al., 1999). Most recently, we determined that misfolded alpha-synuclein 
induces PARP1 activity, thus increasing the levels of PAR and leading to neuronal cell 
death (Kam et al., 2018). PAR is therefore potentially an ideal marker given its role in PD 
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pathophysiology and its importance in cell death. Despite this strong data, the CSF PAR 
levels do not predict cognitive change in this cohort, though this conclusion is mitigated 
by the overall small number of individuals that exhibited cognitive change during our 
current follow up period as well as the loss to follow up of more clinically advanced 
individuals. 
The inverse relationship between PAR levels and a diagnosis of dementia implies 
a complex pattern of PAR concentration over disease course. Based on preclinical data, 
we would hypothesize that PAR levels would rise earlier in the disease course only to 
then decrease as the neurons “burn out” and the rate of neurodegeneration slows down. 
As such, the inverse relationship implies that we are catching our patients on the 
downward slope of their PAR levels, and thus the stage of the disease where their overall 
rate of clinical change would be less than previously. In this scenario, the heterogeneity 
of our cohort would prevent us from identifying this relationship across all of our 
analyses. The implications of this hypothesis are that those with the lowest PAR levels 
among the PD cohort are actually the most clinically demented or advanced patients. 
Subsequent investigations will investigate this hypothesis further as we need a larger 
cohort to determine the pattern of CSF PAR levels overtime and cross sectionally.  
The role and importance of anxiety symptomatology is intriguing. Anxiety among 
individuals with PD is very common, with a lifetime prevalence as high as 49% reported 
among individuals with PD (Pontone et al., 2009). Even more common, though, are 
anxiety symptoms that do not meet the threshold for diagnosis of an anxiety disorder but 
rather symptomatology that impacts function and quality of life (Pontone et al., 2009). 
This is certainly the situation in our cohort, where the mean Hamilton Anxiety Scale 
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score is 10.4 (SD 6.06) even amongst our most anxious group (A score of less than 17 on 
the Hamilton Anxiety Scale is considered mild anxiety (Hamilton, 1959)). Anxiety is 
thought to heighten concentration and attention to tasks that are considered threat-related, 
to the detriment of attention and working memory in other areas (Vytal, Cornwell, 
Letkiewicz, Arkin, & Grillon, 2013). Among individuals with new-onset PD, those with 
anxiety were three times more likely to have cognitive impairment (Dissanayaka et al., 
2017). The relationship between anxiety and levodopa is also complex—patients 
frequently report a heightened anxiety state as their levodopa wears off and as the disease 
worsens, so does anxiety symptomatology (Martinez-Fernandez, Schmitt, Martinez-
Martin, & Krack, 2016). In our cohort, anxiety symptomatology, but not depression 
symptomatology, mitigated the relationship between PAR levels and diagnosis of 
dementia. This is likely due to the overall worsening of anxiety that occurs in conjunction 
with increased disease duration and worsening of cognition. More research is needed in 
this area and in a larger cohort we will be able to explore this complex relationship 
further. 
The search for a biomarker for PD-related cognitive decline has previously 
included primarily the biomarkers used for Alzheimer’s disease (Aasly et al., 2012; 
Backstrom et al., 2015; Biundo, Weis, & Antonini, 2016; Hall et al., 2012; Kang, 2016; 
Kang et al., 2016) as well as alpha-synuclein (Shi et al., 2012; Shi et al., 2014; Simonsen 
et al., 2016). The use of AD-based biomarkers is problematic due to the co-pathology of 
amyloid beta, tau, and alpha-synuclein observed in approximately 40% of individuals 
with PD at autopsy and the known potentiation of abnormal tau and abnormal alpha-
synuclein with each other (Irwin et al., 2013). The positive AD-based markers therefore 
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may represent the AD pathology among our patients more than the PD pathology. By 
contrast, PAR has clearly been shown to be part of the abnormal alpha-synuclein 
pathway. PAR’s role in AD is less well understood and warrants further investigation.  
One of the many things that makes PAR intriguing as a biomarker are the 
availability of PARP1 inhibitors. Three PARP1 inhibitors are currently FDA approved 
for use in gynecologic cancers and are being tested for use in a wide variety of other 
cancers as well as diseases as diverse as pulmonary arterial hypertension and as adjunct 
therapy with tPA in stroke. There are also a number of PARP1 inhibitors that are under 
development for use in cancer and other diseases. These diseases all feature DNA 
fragmentation as a common endpoint and as such benefit from PARP1 inhibition. These 
FDA-approved PARP1 inhibitors also inhibit PARP2 and PARP3 and have various 
amounts of blood brain barrier penetration, thus implying that some of the PARP1 
inhibitors would be more effective than others for a neurodegenerative central nervous 
system disease. The strong preclinical data for PARP1 inhibition continues to make it an 
interesting therapeutic despite the less promising results of CSF PAR as a biomarker 
presented here. Since PARP1 activates PAR, levels are likely responsive to PARP1 
activity. Therefore, PAR levels may be a biomarker for target engagement and we have 
demonstrated the ability to test PAR levels on a reasonably large scale.   
This is the first investigation to our knowledge of whether PAR levels in the CSF 
is a potential biomarker of PDD. Subsequent analysis should evaluate the role of PAR as 
a marker of motor progression and confirm the results presented herein regarding 
cognitive progression. Efforts should also be made to evaluate the role of serum PAR as a 
marker of cognitive and motor decline in PD. While PAR in the CSF is not clearly a 
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marker for cognitive progression, this investigation is nevertheless an exciting step into 


















































Individuals with Parkinson’s disease dementia (PDD) have increased mortality 
above those with Parkinson’s disease (PD) alone. In addition, individuals with PDD are 
less likely to continuing working and more likely to require assisted living. 
Approximately 80% of individuals with PD will have developed PDD by about 15 years 
after symptom onset (Aarsland et al., 2003), with many individuals having developed 
dementia even sooner in their disease course. The pathologic etiology of PDD that has 
been identified thus far includes individuals with only cortical alpha-synuclein and 
individuals who have both cortical alpha-synuclein and cortical amyloid and beta. 
Individuals with these two pathologic types have an earlier mortality compared to 
individuals with alpha-synuclein pathology alone (Irwin et al., 2017; Irwin et al., 2012). 
Vascular pathology has been shown to contribute to dementia in older populations 
outside of those with PD. Autopsy investigations of older adults demonstrate that those 
with vascular pathology, including lacunar and larger infarcts (Breteler, 2000) as well as 
vessel disease and cerebral amyloid angiopathy (Pontes-Neto, Auriel, & Greenberg, 
2012), demonstrate increased rates of dementia compared to those without that 
pathology. In addition, the addition of vascular pathology to underlying Alzheimer’s 
disease (AD) pathology significantly increases the risk of developing dementia. The 
amyloid and tau that make up AD pathology potentiate the development of vascular 
pathology and vice versa (Love & Miners, 2016), thus leading to an overall worsening of 
the individual's cognition. Finally, the relationship is likely reciprocal with mid-life 
vascular risk factors increasing brain amyloid deposition and development of dementia 
(Gottesman, Albert, et al., 2017; Gottesman, Schneider, et al., 2017) 
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Despite the importance of vascular pathology in AD dementia and the 
development of dementia in general, the contribution of vascular pathology to the 
development of PDD has not been fully elucidated. Irwin et al showed no contribution of 
vascular pathology to the development in dementia in alpha-synucleinopathies (Irwin et 
al., 2012) while others have reported that vascular risk factors worsened cognition and 
freezing of gait among individuals with PD (Stojkovic et al., 2018).  This investigation 
sought to determine the role of vascular pathology in the disease duration of PDD, and 
secondarily the role of vascular pathology on the development of PDD. We hypothesized 
that vascular pathology would shorten the disease duration and that individuals with a 
heavier burden of vascular pathology would have an even shorter disease duration than 
those with a more modest vascular burden. We also evaluated whether individuals with 
vascular pathology in general and those with a heavier vascular burden were more likely 
to develop PDD. Finally, we compared our cohort to previous investigations by 
determining whether individuals with Alzheimer’s disease-based pathology, specifically 
amyloid and tau, had both increased odds of dementia or shorter disease duration than 




Participants were part of the Morris K. Udall Parkinson’s Disease Research 
Center of Excellence research study. This investigation is approved by the Johns Hopkins 
School of Medicine Institutional Review Board. The Udall Center enrolls individuals 
with PD, atypical PD, and controls and obtains autopsies at the time of their death. 
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Participants included in this analysis participated in the Udall Center’s Longitudinal 
study, which also includes clinical, motor, cognitive, and psychiatric assessments from 
the time of enrollment and every other year until the time of autopsy. The research 
investigation began in 1999 and has been ongoing since that time. This analysis included 
only those individuals who had autopsy-proven PD pathology at the time of their death 
and used the cognitive, motor, and psychiatric testing from their in-person research visit 
closest to their time of death.  
 
Cognitive impairment 
Dementia was defined according to the criteria laid out by the 2007 Movement 
Disorder task force (Emre et al., 2007). Briefly, that manuscript states that individuals 
probable PDD must have the core criteria of first be diagnosed with PD according to UK 
Brain Bank Criteria, and then also have a dementia syndrome with insidious onset and 
slow progression. They also must have impairment in more than one cognitive domain 
that is a decline from premorbid level with cognitive deficits severe enough to impair 
daily life. Diagnosis may also include behavioral symptoms that support the diagnosis. 
We operationalized these criteria by dividing the diagnosis into specific categories and 
then insuring that any participant we defined as dementia met the probable PDD 
dementia diagnostic criteria.  All those that did not meet the definition of dementia were 
defined as simply not demented. Given the small numbers, we did not differentiate 
between those with mild cognitive impairment and those with normal cognition. During 
this process, we did not include reports of cognitive change that occurred within 2 




Disease duration and other variables 
 Disease duration was defined as the time from disease diagnosis to death. For the 
majority of the analyses, disease duration was treated as a continuous variable. We also 
divided disease duration into quartiles and compared the highest and lowest quartile with 
respect to the role of vascular pathology increasing the odds of being in the higher or 
lower disease duration group.  
 
Pathology 
Autopsies were conducted by the Division of Neuropathology at Johns Hopkins 
using the most up-to-date staining and diagnostic criteria at the time of autopsy. Autopsy 
methods have been described elsewhere (Mills et al., 2016). Briefly, after fixing in 10% 
buffered formaldehyde tissue blocks were processed, cut at 10-micrometers and stained 
with H&E. Subsequently, selected sections were silver-stained (Hirano method) and 
immunostained against phosphorylated anti-Tau (PHF-1)(a gift of Dr. Pater Davies) as 
part of our efforts to identify AD pathology and alpha-synuclein (Transduction 
laboratories) as part of our efforts to identify PD pathology. The subsequent 
determination of pathologic type and severity followed the 2012 McKeith Criteria 
(McKeith et al., 2017for the Lewy body pathology and we used both CERAD criteria ; 
Mirra et al., 1991) and Braak levels (Braak, Alafuzoff, Arzberger, Kretzschmar, & Del 
Tredici, 2006)for the AD-based pathology. For the CERAD criteria, participants were 
stratified into possible, probable and definite AD contributing to their cognitive change, 
with additional analysis grouping the probable and definite AD groups together. For the 
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Braak staging-based analysis, we grouped those with low (Braak stage 0-II), middle 
(Braak stage III-IV) and high (Braak stage  V- VI) neurofibrillary pathology together. 
For the vascular pathology, the neuropathologists noted the presence or absence 
of atherosclerosis and arteriosclerosis, significant obstruction of large vessels, gross 
evidence of other vascular lesions including aneurysms, infarcts less than and larger than 
10 mm, parenchymal hemorrhages, and sometimes vascular lesion location. They also 
looked specifically at cerebral atherosclerosis, cerebral amyloid angiopathy, and the 
presence of other microvascular disease or microinfarcts not noted elsewhere. They also 
determined, along with the other pathologic data and cognitive testing data, whether they 
believed that vascular lesions contributed to the development of antemortem cognitive 
impairment. We operationalized these criteria in the following manner: First, we grouped 
together as a common endpoint any brain that showed vessel obstruction, parenchymal 
vascular lesions, large or lacunar infarcts, hemorrhages cerebral atherosclerosis, and other 
microvascular disease and other microvascular infarcts. Presence of any of these 
pathologies was termed as presence of CVD pathology. We did not include general 
atherosclerosis since we have a variable for the more specific and relevant cerebral vessel 
atherosclerosis, nor did we include arteriosclerosis or cerebral amyloid angiopathy 
(CAA) in this initial analysis. In the case of CAA, we do not have any data on the 
severity of CAA and the presence of CAA was very common in our cohort. We therefore 
created an additional composite variable that included everything in our initial 
cerebrovascular disease positive group plus those who were CAA positive, thus allowing 
us to consider the contribution and importance of CAA in general in our population both 
separate from and in combination with other forms of cerebrovascular disease.  To 
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determine cerebrovascular disease severity, individuals were given 1 point for the 
presence of each of the vascular pathologies we have been calculating (vessel obstruction 
greater than 50%, parenchymal vascular lesions, large infarcts, lacunar infarcts, 
hemorrhages, cerebral atherosclerosis, other microvascular disease, other microinfarcts, 
cerebral amyloid angiopathy) and the total vascular burden was a sum of each person’s 
vascular pathology. This CVD burden score therefore ranged from 0 to 9. 
 
Statistical Analysis 
Demographic and pathologic characteristics between individuals with PD pathology 
versus those with PD and AD pathology were compared using Student’s t-test or Chi-
squared as appropriate. For this analysis, those with AD pathology were considered to be 
those with probable or definite AD based on the CERAD criteria. We restricted our initial 
analysis in which disease duration was our outcome to those with PDD at their last 
clinical visit. After confirming that disease duration was normally distributed, we 
subsequently set up a simple linear regression of disease duration and our three forms of 
vascular pathology (CVD presence, amyloid angiopathy, and CVD burden). With each of 
these, we subsequently set up an additional linear regression controlling for age, gender, 
education, and UPDRS motor subscore. We set up the same simple and multiple logistic 
regression comparing the odds of being in the highest quartile of disease duration to 
being in the lowest quartile of disease duration. Finally, to evaluate whether vascular 
disease increased the odds of developing dementia, we set up a simple and then multiple 
logistic regression looking at each of our vascular disease subtypes and then controlling 






 Since 1999, we have had 67 individuals from the Longitudinal Study with 
sufficient information to confirm cognitive diagnosis come to autopsy with pathologically 
proven PD. Among those individuals, 56 had confirmed dementia at the time of their last 
research visit while the remaining 11 had MCI at that time.  Among those with PDD at 
the time of the last research visit, there was no difference in age, gender, race, disease 
duration, UPDRS motor score, anxiety and depression symptomatology, disease duration, 
and time from last research visit to autopsy (p>0.05) between those with PD pathology 
(n=31) and those with PD and AD pathology (n=25) (Table 5). AD pathology was 
defined as possible or definite AD based on CERAD criteria.  
We further compared those with PD-MCI versus those with PDD. Individuals 
with PD-MCI were more less likely to be men (PD-MCI 27.28% men, PDD 71,43% men, 
p<0.01), had lower UPDRS motor sub scores (PD-MCI 29.22 (SD 12.09), PDD 46.11 
(SD 18.26), p=0.01), had lower UPDRS total scores (PD-MCI 46.22 (SD 13.20), PDD 
85.52 (SD 26.03), p<0.01), and a shorter disease duration (PD-MCI 13.09 years (SD 
5.20), PDD 17.36 years (SD 6.24), p=0.03). The PD-MCI and PDD groups were evenly 
matched with regards to education (PD-MCI 15.64 years (SD 2.29), PDD 16.23 years 
(SD 3.47), p=0.58), race (PD-MCI 90% Caucasian, PDD 96% Caucasian, p=0.13), age at 
death (PD-MCI 81.82 years (SD 7.93), PDD 78.30 years (SD 7.41), p=0.16), Hamilton 
Anxiety scale total score (PD-MCI 6.80 (SD 5.07), PDD 9.75 (SD 6.20), p=0.16), Beck 
Depression Inventory score (PD-MCI 6.11 (SD 3.76), PDD 9.63 (SD 6.84), p=0.14), and 
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months from last visit to autopsy (PD-MCI 35.00 months (SD 28.04), PDD 25.02 months 
(SD 17.99), p=0.13).   
 
Pathology summary 
 Among individuals with PDD at their last research visit prior to autopsy, 22 had 
no AD pathology per CERAD criteria, 9 had possible AD, 20 and probable AD, and 5 
had definite AD.  Using the Braak staging for neurofibrillary tangles, 5 individuals had 
Braak stage 1, 15 individuals had Braak stage II, 14 individuals had Braak stage III, 19 
individuals had Braak stage 4, and 1 individuals had Braak stage VI (no autopsy showed 
Braak stage V, Braak staging data was not available for 2 individuals).  Among 
individuals with probable or definite AD by CERAD criteria, 4 individuals had Braak 
stage II, 7 individuals had Braak stage III, 13 individuals had Braak stage IV and 1 
individuals had Braak stage IV.  The overwhelming majority of autopsies from both the 
PD path and the PD and AD path group had cortical level Lewy bodies (41 of the 56 
autopsies,  73%). About 45% of the cohort had some form of vascular pathology, with 
that number increasing to 71% when CAA is included. There was a significant difference 
between the PD path and the PD and AD path with regards to the percent of autopsies 
with CAA (p=0.05). CVD burden was similar between the two groups, with the largest 
number of individuals demonstrating 2 different forms of cerebrovascular disease (18 of 
the 56 individuals with PDD, or 32%). See Table 6 for additional details regarding the 





 In separate simple linear regressions, neither cerebrovascular disease, CAA, or 
overall CVD burden were significantly associated with disease duration among our PDD 
cohort (CVD beta 1.16 (95% CI -2.22, 4.59), p=0.49; CAA beta -1.04 (95% CI -4.61, 
2.53), p=0.56, CVD burden beta 0.36 (95% CI -1.03, 1.74), p=0.61). When controlling 
for age, education, race UPDRS motor sub scores, Lewy body level, and different forms 
of AD pathology (both CERAD and Braak staging), cerebrovascular disease, CAA, and 
overall CVD burden continued to not contribute to changes in disease duration (Table 7).   
Our model also did not show a significant relationship between Lewy body level or AD 
pathology and disease duration. 
 We further looked at disease duration in strata, comparing the highest and lowest 
quartile of disease duration. In separate simple logistic regression, presence of 
cerebrovascular disease, CAA, or overall CVD burden did not increase the odds of being 
in the lowest or highest quartile of disease duration ((CVD OR 1.52 (95% CI -0.36, 6.60), 
p=0.57; CAA OR 0.86 (95% CI 0.19, 3.88), p=0.84, CVD burden OR 1.21 (95% CI 0.67, 
2.17), p=0.53). When controlling for age, education, race, UPDRS motor sub scores, 
Lewy body level, and different forms of AD pathology (both CERAD and Braak 
staging), cerebrovascular disease, CAA, and overall CVD burden did not increase the 
odds of being in either the lowest or highest quartile of disease duration (data not shown, 
similar to Table 7). There was a trend toward individuals with a higher AD CERAD score 
having an increased odds ratio of being in the highest quartile of disease duration (i.e. the 
longer disease duration) but this was not significant.  
 We next sought to evaluate these same demographic and pathologic variables 
regarding their association with development of PDD over MCI. In simple logistic 
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regression, presence of cerebrovascular disease and presence of CAA were not associated 
with development of PDD over MCI (CVD OR 1.61 (95% CI 0.43, 5.98), p=0.48; CAA 
OR 6.46 (95% CI 0.74, 56.45)) but presence of 2 forms of vascular pathology (i.e. a CVD 
burden score of 2) resulted in a 9 times greater odds ratio of development of PDD over 
PD-MCI (OR 9.00, (95% CI 1.03 – 78.57), p=0.04) and for every one point increase in 
CVD burden, participants had a 2.10 increased odds of having PDD over PD-MCI (OR 
2.10, (95% CI 1.07 – 4.12), p=0.03). When controlling for age at time of death, gender, 
education, race Lewy body level, AD CERAD score, disease duration, Beck Depression 
Inventory score, Hamilton Depression Score, and time from last research visit to autopsy, 
increased CVD burden continued to increase the odds of developing PDD over PD-MCI 
(OR 4.50 (95% CI 1.14 – 17.68), p=0.03) (Table 8).  
 
Discussion 
While we failed to find a relationship between vascular pathology and disease 
duration, we did find that cerebrovascular burden increased the odds of developing 
dementia over mild cognitive impairment in our PD cohort. The presence of vascular 
pathology and overall vascular burden did not shorten the time from symptom onset to 
death nor did increased Lewy body level and CERAD level. The increased Lewy body 
level and CERAD level also did not predict conversion to PDD from PD-MCI.  
The importance of CVD burden is intriguing as it adds on to others more recent 
findings regarding the role of cerebrovascular risk. Schwartz et al found that pallor in the 
Globus Pallidus internus was significantly associated with higher Hoehn and Yahr scores 
and that the number of vascular risk factors (i.e. hypertension, etc.) predicted dementia 
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(Schwartz, Halliday, Soh, Cordato, & Kril, 2018). They did not find an association 
between small vessel disease, defined as perivascular pallor, gliosis, hyaline thickening, 
and enlargement of perivascular spaces, and the presence of dementia. Our findings of 
the role of cerebrovascular burden and development of dementia differ from this 
manuscript for a number of reasons. 1) The clinical analysis of our cohort is more 
uniform as the same set of raters (YS, CB, LR) reviewed each autopsy case regarding 
their final cognitive strata, 2) the participants in the research study were evaluated by 
movement disorder experts and 3) most importantly our investigation evaluated all forms 
of cerebrovascular disease, not just small vessel disease. It is therefore more 
comprehensive with regards to the impact of cerebrovascular risk factors on pathology 
and, ultimately, on cognition. We suspect that their finding that pathology did not 
correlate with dementia is because they were not looking at the many varied forms of 
cerebrovascular pathology.  
The important clinical question then is how to go about mitigating CVD risk 
factors and there is growing evidence that what truly matters in the importance of 
vascular risk factors and cognition, is middle age health. Growing evidence indicates that 
the pathophysiology of middle age hypertension, hyperlipidemia, and diabetes alters the 
vascular architecture in the brain, thus causing cognitive impairment 10, 20, and even 30 
years later. While we have a few individuals in our autopsy cohort that we have been 
following for more than 15 years, the numbers are not large enough to form any 
meaningful conclusions and there are no PD-based cohorts with ongoing follow up that 
can address these questions. The field would benefit from such an investigation both to 
better understand vascular modification of cognitive impairment and to address other 
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long-term questions.  Even in the absence of a larger, long term cohort study, future 
research should consider vascular risk factors as they contribute to the development of 
dementia.   
Our results should be interpreted with caution given the overall low numbers of 
individuals with PD-MCI and the differences between our cohort and the cohorts of other 
earlier investigations of pathology and PDD. Specifically, our cohort was not 
demonstrating the importance of Lewy body level and AD disease burden on the 
development of PDD and on shortening disease duration. We suspect this is because the 
majority of our patients had cortical Lewy bodies and probable AD, thus decreasing our 
ability to detect differences. The CVD burden score was more evenly distributed across 
the cohort.  
The analysis of vascular pathology as a contributor to PDD continues to be a 
valuable exploration. Vascular disease and vascular risk factors are modifiable and 
therefore are currently the most treatable part of the PD pathology puzzle. This 
investigation indicates a role of vascular burden with regards to development of dementia 
therefore emphasizing the potential role of risk factor modification in the treatment and 
prevention of cognitive impairment in our patients.  It is worth further pursuit of this 
topic as addressing vascular risk has an immediate impact on patient care and could 
potentially improve outcomes. Further exploration of both our and other cohorts are a 
































The fear that patients experience when they are diagnosed with PD is frequently 
palpable in the examination room when having that discussion. The concerns focus 
primarily on what is going to happen to them in the future, how quickly will their disease 
progress and what modifications to their life will need to be made. In addition to 
understandable concerns over worsened quality of life and increased mortality, the 
biggest fear of our patients is worsening of their cognition and development of dementia. 
This cognitive change robs patients and their families of their quality of life and who they 
are as individuals arguably more so than the physical manifestations of the disease. The 
investigations presented here sought to improve the diagnosis, prognostication, and 
understanding of the development of PDD.  
We have learned that PAR may not be an ideal biomarker for PDD but that CVD 
burden may influence development of PDD. As such, these studies both move the field 
forward. Specifically, the investigation of PAR continues. It is clear that the relationship 
between the c-Abl pathway and PD pathophysiology is complex and likely not linear and 
larger cohorts are needed to determine with certainty that PAR is or is not a biomarker of 
cognitive decline. This further investigation should be done concurrently with 
investigation into PARP1 inhibitors—our current patients demand no less than our full 
commitment to moving toward better treatments as soon as possible. It is also clear that 
the role of vascular pathology and vascular risk factors is more complex in our PD 
patients than has been shown in Alzheimer’s disease patients and the general aging 
population. Larger cohorts and cohorts that specifically target groups that have been 
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poorly represented in our and other autopsy studies would be incredibly beneficial to the 














































Table 1. Baseline demographic and clinical characteristics of Parkinson’s disease and control 
participants in the JHU PDBP cohort 
 Parkinson’s disease (n=86) Healthy Controls (n=35) p-value 
Age, years (SD) 66.08 (8.17) 66.84 (8.86) 0.65 
Education, years (SD) 16.82 (2.39) 16.84 (2.33) 0.95 
Gender, % Male 69.8 31.42 <0.01 
Race, % Caucasian 95.34 88.57 0.17 
MDS-UPDRS motor score, 
mean (SD) 
32.13 (11.86) 1.51 (2.02) <0.01 
MDS-UPDRS total score, 
mean(SD) 
60.30 (24.19) 6.8 (6.18) <0.01 
Total LED, mean (SD) 731.00 (497.88) -- -- 
Hamilton Anxiety Score total, 
mean (SD)  
7.77 (4.31) 4.23 (4.01) <0.01 
Hamilton Depression Score 
total, mean (SD) 
6.32 (4.62) 3.29 (3.75) <0.01 
MoCA total score, mean (SD) 25.46 (4.54) 27.77 (1.24) 0.04 
Cognition, number of 
individuals 
25 Normal Cognition 
45 Mild Cognitive Impairment 
15 Dementia 
27 Normal Cognition 
8 Mild Cognitive 
Impairment 
<0.01 


















Mean follow-up time, years 
(SD) 
2.96 (1.56) 3.02 (1.54) 0.71 
Mean disease duration, years 
(SD) 
6.79 (4.83) -- -- 
MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; 
LED=Levodopa Equivalent Dose; MoCA=Montreal Cognitive Impairment; UPSIT=University  of 
Pennsylvania Smell Identification Test. See appendix for score range of each assessment. 
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 Table 2. Baseline demographic and clinical characteristics of Parkinson’s disease-normal 
cognition, Parkinson’s disease-mild cognitive impairment and Parkinson’s disease dementia 
participants in the JHU PDBP cohort 







Age, years (SD) 60.67 (7.84) 66.29 (6.17) 73.84 (7.56) <0.01 
Education, years (SD) 16.76 (2.18) 16.78 (2.57) 16.93 (2.89) 0.97 
Gender, % Male 52 73 93 0.02 
Race, % Caucasian 100 93 93 0.42 
MDS-UPDRS motor 
score, mean (SD) 
27.00 (8.76) 30.22 (9.71) 47.47 (9.83) <0.01 
MDS-UPDRS total 
score, mean(SD) 
51.72 (11.67) 54.91 (17.78) 91.33 (32.62) <0.01 







Hamilton Anxiety Score 
total, mean (SD)  
6.72 (5.00) 7.33 (3.60) 10.8 (4.77) 0.50 
Hamilton Depression 
Score total, mean (SD) 
5.76 (4.39) 5.23 (3.32) 10.40 (6.06) <0.01 
MoCA total score, mean 
(SD) 

















UPSIT total score, mean 
(SD) 
20.76 (6.05) 19.12 (7.07) 14.00 (7.13) 0.01 
Mean follow-up time, 
years (SD) 
3.05 (1.67) 3.06 (1.43) 2.30 (1.62) 0.43 
Mean disease duration, 
years (SD) 
6.91 (4.20) 5.65 (4.04) 9.04 (5.99) 0.04 
MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; 
LED=Levodopa Equivalent Dose; MoCA=Montreal Cognitive Impairment; UPSIT=University of 






Table 3. Baseline demographic and clinical characteristics comparing individuals whose cognition remained 
stable and those whose cognition progressed to either PD-MCI or PDD during follow-up time among 
individuals in the JHU PDBP cohort 
 Stable cognition (n=44) Cognitive decline (n=26) p-value 
Age, years (SD) 63.57 (6.97) 65.50 (7.78) 0.29 
Education, years (SD) 16.97 (2.31) 16.42 (2.32) 0.34 
Gender, % Male 70 58 0.28 
Race, % Caucasian 85 96 0.89 
MDS-UPDRS motor score, mean (SD) 27.63 (9.64) 31.50 (8.75) 0.10 
MDS-UPDRS total score, mean(SD) 50.50 (15.38) 59.31 (15.36) 0.02 
Total LED, mean (SD) 655.18 (482.62) 839.97 (431.54) 0.11 
Hamilton Anxiety Score total, mean (SD)  6.86 (3.40) 7.52 (4.76) 0.51 
Hamilton Depression Score total, mean 
(SD) 
5.05 (2.97) 6.08 (4.77) 0.27 
MoCA total score, mean (SD) 27.36 (2.10) 25.96 (2.09) <0.01 
UPSIT total score, mean (SD) 20/26 (7.34) 18.80 (5.66) 0.40 
Mean disease duration, years (SD) 5.05 (3.59) 7.89 (4.40) <0.01 
MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; LED=Levodopa 









Table 4. Results of the final multiple regression analysis evaluating which independent variable 
predicted change in cognitive status. PAR concentration did not predict change in cognition.  
Independent variables Odds Ratio 95% CI p-value 
PAR at Visit 1 1.01 0.99,  1.02 0.30 
PAR concentration throughout follow up time 1.01 0.99,   1.02 0.30 
MoCA at Visit 1 0.57 0.40,   0.82 <0.01 
Total LED 1.00 0.99,    1.00 0.61 
Disease duration 1.25 0.99,   1.58 0.06 
Age at baseline visit 1.01 0.91,    1.11 0.86 
Gender 0.39 0.09,  1.60 0.19 
Education 0.87 0.49,   1.55 0.64 
Race 0.19 0.02,  2.24 0.19 
Hamilton Depression Scale 1.00 0.78,   1.29 0.98 
Hamilton Anxiety Scale 1.03 0.78,    1.37 0.83 







Table 5. Demographic and clinical characteristics of individuals with pathologically proven Parkinson’s 
disease, comparing those with and without additional AD pathology.  
 PD pathology  
(n=31) 
PD and AD pathology  
(n=25) 
p-value 
Age at death, years (SD) 77.77 (8.09) 78.96 (6.57) 0.56 
Time between last research visit 
and autopsy, months (SD) 
24.94 (17.59) 25.12 (18.84) 0.97 
Education, years (SD) 16.65 (3.80) 15.72 (3.01) 0.33 
Gender, % Male 71.07 72.00 0.93 
Race, % Caucasian 96.80 96.00 0.88 
UPDRS motor score at last visit, 
mean (SD) 
43.67 (15.56) 48.90 (20.98) 0.34 
UPDRS total score, mean(SD) 85.52 (20.47) 85.52 (31.55) 0.99 
Hamilton Anxiety Score total, mean 
(SD)  
10.26 (6.11) 9.10 (6.41) 0.52 
Beck Depression Inventory total, 
mean (SD) 
8.9 (7.92) 10.22 (5.96) 0.60 
Mean disease duration, years (SD) 18.13 (6.41) 19.52 (6.97) 0.44 
MDS-UPDRS=Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; LED=Levodopa 















Table 6.  Pathological characteristics of individuals with pathologically proven Parkinson’s disease, 
comparing those with and without additional AD pathology 
 PD only 
(n=31) 
PD and AD pathology 
(n=25) 
p-value 









Presence of CVD*, % 
45 44 0.93 
Presence of CAA, % 36 64 0.05 
CVD presence* and CAA, %  
81 60 0.09 
CVD burden**, number of individuals 
with each burden level  
0, 1 individual 
1, 12 individuals 
2, 9 individuals 
3, 4 individuals 
4, 3 individuals 
5, 2 individuals 
0, 2 individuals 
1, 4 individuals 
2, 9 individuals 
3, 8 individuals 
4, 1 individuals 
5, 1 individual 
0.27 
*CVD (Cerebrovascular disease) defined as presence of any of the following: vessel obstruction greater 
than 50%, parenchymal vascular lesions, large infarcts, lacunar infarcts, hemorrhages, cerebral 
atherosclerosis, other microvascular disease, other microinfarcts. **CVD burden is the sum of each of 










Table 7. Results of three final multiple regressions analyzing which independent variable predicted disease duration. 











95% CI p-value Beta 
coefficien
t 
95% CI p-value 
     Model 1    Model 2    Model 3 
Age -0.06 -0.34,  0.23 
0.68 0.06 -0.28,  
0.39 
0.74 -0.05 -0.34, 
0.24 
0.72 
Education 0.31 -0.44,  1.07 
0.41 0.19 -0.59,   
0.97 




-0.68 -5.49,  
4.14 
0.77 -1.40 -6.88,   
4.09 













0.13 0.02,   
0.25 
0.02 0.11 -0.02,   
0.25 


































Possible AD1  
2.95 -1.10,   
7.00 
0.14 3.94 -0.68,   
8.56 





2.99 -1.09,   
7.07 
0.15       
CAA    -1.83 -6.64,   2.97 
0.44    
CVD 
burden** 




0.05 0.02 0.01 
 1Possible or probable AD based on CERAD criteria. UPDRS=Unified Parkinson’s Disease Rating Scale; 
AD=Alzheimer’s disease; CAA=Cerebral amyloid angiopathy 
*CVD (Cerebrovascular disease) defined as presence of any of the following: vessel obstruction greater than 50%, 
parenchymal vascular lesions, large infarcts, lacunar infarcts, hemorrhages, cerebral atherosclerosis, other 
microvascular disease, other microinfarcts.  














Table 8. Results of the final multiple regression analyses evaluating which independent variable predicted 
conversion from PD-MCI to PDD.   
Independent variables Odds Ratio 95% CI p-value 
Age 0.91 0.76,   1.09 0.31 
Education 0.82 0.50,    1.37 0.45 
Gender 0.04 0.00,   1.02 0.05 
Race 2.79 0.11, 72.48 0.54 
Disease Duration 1.11 0.90,  1.36 0.33 
Time from last research visit to autopsy 1.00 0.93, 1.08 0.91 
Beck Depression Inventory 1.00 0.99 ,  1.01 0.10 
Hamilton Anxiety Scale  1.00 0.99,  1.01 0.11 
Lewy body level 3.97 5.17 
0.04,  374.35 
0.15,  189.66 
0.55 
0.37 
Probable or Possible AD1  1.50 0.41,    5.38 0.54 
CVD burden 4.50 1.15, 17.69 0.03 































Figure 2. Comparison of mean poly (ADP-ribose) concentration between individuals with 









































Assessment of PAR missingness 
 
*    Missing-value patterns for PAR 
 *       (1 means complete) 
 
             * |   Pattern 
   *  Percent   |  1  2  3  4    5  6 
   *------------+--------------------- 
   *     <1%    |  1  1  1  1    1  1 
   *            | 
   *     31     |  1  1  1  0    0  0 
   *     23     |  1  1  1  1    0  0 
   *     19     |  1  1  0  0    0  0 
   *     11     |  1  0  0  0    0  0 
   *      7     |  0  0  0  0    0  0 
   *      3     |  1  1  0  1    0  0 
   *      2     |  1  0  1  0    0  0 
   *      2     |  1  0  1  1    0  0 
   *     <1     |  0  1  0  1    0  0 
   *     <1     |  0  1  1  0    0  0 
   *------------+--------------------- 
   *    100%    | 
 
 
Assessment of differences between those with no PAR levels (n=10) and those with 
PAR levels (n=111): 
 
No difference in  
-age (mean no PAR level, 64.13 years SD 9.38 years; mean with PAR levels 
66.49 years SD 8.26 years; p=0.39)  
-gender (10% of women have no PAR levels, 9.8% of men have no PAR levels, 
p<0.01) 
-case/control status (7% of cases do not have PAR levels, 11.4% of controls 
do not have PAR levels, p=0.42) 
 
 
Assessment of follow up and subsequent bias: 
Mean age of PD patients: 
 Visit 1: 66.08 years 
 Visit 2: 67.21 years 
 Visit 3: 67.68 years 
 Visit 4: 68.34 years 
 Visit 5: 69.41 years 
 Visit 6: 70.19 years 
In other words, over 6 years of follow up our mean age only increased by about 4 
years. Our older participants were more likely to drop out. 
 
% male of PD patients:  
 Visit 1: 69.77% 
 Visit 2: 71.60% 
 Visit 3: 69.86% 
 Visit 4: 65.08% 
 Visit 5: 63.26% 
 Visit 6: 53.84% 
In other words, over 6 years our % males decreased from about 70% to about 53%. 




MoCA score of PD patients: 
 Visit 1: 25.46 
 Visit 2: 25.64 
 Visit 3: 26.52 
 Visit 4: 26.38 
 Visit 5: 26.18 
 Visit 6: 25.42 
In other words, no change in MoCA score over the course of the investigation. 
This seems unlikely among PD patients. More likely, the individuals with lower 
MoCA scores dropped out. 
 
MDS-UPDRS part III score of PD patients: 
 Visit 1: 32.13 
 Visit 2: 31.03 
 Visit 3: 31.12 
 Visit 4: 32.58 
 Visit 5: 30.14 
 Visit 6: 29.92 
In other words, over 6 years of follow up our cohort improved by more than 2 
points in the MDS-UPDRS part III score. Our more advanced patients clearly dropped 
out of the investigation. 
 








Supplemental Table 1. Normal score ranges for the assessments in these 
investigations 
Test Range  
MDS-UPDRS part III (motor)  0-132 
MDS-UPDRS total score (part I, II, III, IV) 0-260  
Hamilton Anxiety Rating Scale  0-56 
Hamilton Depression Rating Scale  0-50 
MoCA  0-30 
UPDRS part III (motor) 0-108 
UPDRS total (pats I, II, III, IV)  0-199 
UPSIT  0-40 
Beck Depression Scale  0-63  
Abbreviations: UPDRS: Unified Parkinsons Disease Rating Scale; MDS-UPDRS: Movement 
Disorder Society-Unified Parkinsons Disease Rating Scale; MoCA: Montreal Cognitive 
Impairment; UPSIT: University of Pennsylvania Smell Identification Test 
Note: For both the MoCA and the UPSIT, higher scores reflect better performance. For all other 




Permission is required to use the MDS-developed Rating Scales (with the exception of 
personal/individual use). Reproduction, translation, modification, sale, or distribution of any 
portion of the MDS Rating Scales is strictly prohibited. MDS Rating Scales may not be 
incorporated into clinical trials, training or certification programs or materials, software programs, 
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The Movement Disorder Society (MDS)-sponsored new version of the UPDRS is founded on the critique 
that was formulated by the Task Force for Rating Scales in Parkinson’s disease (Mov Disord 2003;18:738-750). 
Thereafter,  the  MDS  recruited  a  Chairperson  to  organize  a  program  to  provide  the  Movement  Disorder 
community with a new version of the UPDRS that would maintain the overall format of the original UPDRS, but 
address  issues  identified  in  the  critique  as  weaknesses  and  ambiguities.  The Chairperson i d e n t i f i e d  
subcommittees with chairs and members. Each part was written by the appropriate subcommittee members 
and then reviewed and ratified by the entire group. These members are listed below. 
 
 
The MDS-UPDRS has four parts:   Part I (non-motor experiences of daily living), Part II (motor 
experiences of daily living, Part III (motor examination) and Part IV (motor complications).   Part I has two 
components: IA concerns a number of behaviors that are assessed by the investigator with all pertinent 
information from patients and caregivers, and IB is completed by the patient with or without the aid of the 
caregiver, but independently of the investigator.  These sections can, however, be reviewed by the rater to 
ensure that all questions are answered clearly and the rater can help explain any perceived ambiguities. Part II 
is designed to be  a  self-administered  questionnaire  like  Part  IB,  but  can  be  reviewed  by  the 
investigator  to  ensure  completeness and clarity. Of note, the official versions of Part IA, Part IB and Part II of 
the MDS-UPDRS do not have separate on or off ratings.  However, for individual programs or protocols the same 
questions can be used separately for on and off. Part III has instructions for the rater to give or demonstrate 
to the patient; it is completed by the rater.  Part IV has instructions for the rater and also instructions to be read 
to the patient. This part integrates patient-derived information with the rater’s clinical observations and judgments 
and is completed by the rater. 
The authors of this new version are: 
Chairperson: Christopher G. Goetz 
Part I: Werner Poewe (chair), Bruno Dubois, Anette Schrag 
Part II: Matthew B. Stern (chair), Anthony E. Lang, Peter A. LeWitt 
Part III:  Stanley Fahn (chair), Joseph Jankovic, C. Warren Olanow 
Part IV: Pablo Martinez-Martin (chair), Andrew Lees, Olivier Rascol, Bob van Hilten 
Development Standards: Glenn T. Stebbins (chair), Robert Holloway, David Nyenhuis 
Appendices: Cristina Sampaio (chair), Richard Dodel, Jaime Kulisevsky 
Statistical Testing: Barbara Tilley (chair), Sue Leurgans, Jean Teresi, 
Consultant: Stephanie Shaftman, Nancy LaPelle 
 
Contact person: Christopher G. Goetz, MD 
Rush University Medical Center 
1725 W. Harrison Street, Suite 755 
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Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) 
 
Overview: This portion of the scale assesses the non-motor impact of Parkinson's disease (PD) on patients’ 
experiences of daily living. There are 13 questions. Part 1A is administered by the rater (six questions) and focuses 
on complex behaviors. Part 1B is a component of the self-administered Patient Questionnaire that covers seven 
questions on non-motor experiences of daily living. 
 
Part 1A: 
In administering Part IA, the examiner should use the following guidelines: 
 
1.  Mark at the top of the form the primary data source as patient, caregiver, or patient and caregiver in equal 
proportion. 
2.  The response to each item should refer to a period encompassing the prior week including the day on which the 
information is collected. 
3. All items must have an integer rating (no half points, no missing scores). In the event that an item does not 
apply or cannot be rated (e.g., amputee who cannot walk), the item is marked UR for Unable to Rate. 
4. The answers should reflect the usual level of function and words such as “usually”, “generally”, “most of the time” 
can be used with patients. 
5. Each question has a text for you to read (Instructions to patients/caregiver). After that statement, you can 
elaborate and probe based on the target symptoms outlined in the Instructions to examiner. You should NOT 
READ the RATING OPTIONS to the patient/caregiver, because these are written in medical terminology. From 
the interview and probing, you will use your medical judgment to arrive at the best response. 
6. Patients may have co-morbidities and other medical conditions that can affect their function. You and the patient 
must rate the problem as it exists and do not attempt to separate elements due to Parkinson’s disease from other 
conditions. 
 
EXAMPLE OF NAVIGATING THROUGH THE RESPONSE OPTIONS FOR PART 1A 
 
Suggested strategies for obtaining the most accurate answer: 
After reading the instructions to the patient, you will need to probe the entire domain under discussion to determine 
Normal vs. problematic: If your questions do not identify any problem in this domain, record 0 and move on to the 
next question. 
 
If your questions identify a problem in this domain, you should work next with a reference anchor at the mid-range 
(option 2 or Mild) to find out if the patient functions at this level, better or worse. You will not be reading the choices of 
responses to the patient as the responses use clinical terminology. You will be asking enough probing questions to 
determine the response that should be coded. 
 
Work up and down the options with the patient to identify the most accurate response, giving a final check by 
excluding the options above and below the selected response. 
 
 
Is this item normal for you? 
 
‘No, I have problems.’ 
 
Consider mild (2) as a reference point 
and then compare with slight (1). 
 
If mild is closer than slight. 
 
Consider moderate (3) to see if this 
answer fits better. 
 
If moderate is closer than mild. 
 
Consider severe (4) to see if this 


















‘No, severe is too severe’. 
 





















‘Yes, severe is closest.’ Confirm and mark (4) Severe.
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Patient Name or Subject ID 
 
 
     _______________ 
Site ID 
 












Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) 
 
Part 1A: Complex behaviors: [completed by rater] 
 
Primary source of information: 
 
 Patient  Caregiver  Patient and Caregiver in Equal Proportion 
 
To be read to the patient: I am going to ask you six questions about behaviors that you may or may not experience. 
Some questions concern common problems and some concern uncommon ones. If you have a problem in one of the 
areas, please choose the best response that describes how you have felt MOST OF THE TIME during the PAST 
WEEK. If you are not bothered by a problem, you can simply respond NO. I am trying to be thorough, so I may ask 
questions that have nothing to do with you. 
 
1.1 COGNITIVE IMPAIRMENT 
 
Instructions to examiner: Consider all types of altered level of cognitive function including cognitive 
slowing, impaired reasoning, memory loss, deficits in attention and orientation. Rate their impact on 
activities of daily living as perceived by the patient and/or caregiver. 
 
Instructions to patients [and caregiver]: Over the past week have you had problems remembering things, 
following conversations, paying attention, thinking clearly, or finding your way around the house or in 
town? [If yes, examiner asks patient or caregiver to elaborate and probes for information.] 
 
 
0: Normal: No cognitive impairment. 
 
1: Slight: Impairment appreciated by patient or caregiver with no concrete interference with 
the patient’s ability to carry out normal activities and social interactions. 
 
2: Mild: Clinically evident cognitive dysfunction, but only minimal interference with 
the patient’s ability to carry out normal activities and social interactions. 
 
3: Moderate: Cognitive deficits interfere with but do not preclude the patient’s ability to carry 
out normal activities and social interactions. 
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1.2 HALLUCINATIONS AND PSYCHOSIS 
 
Instructions to examiner: Consider both illusions (misinterpretations of real stimuli) and hallucinations 
(spontaneous false sensations). Consider all major sensory domains (visual, auditory, tactile, olfactory 
and gustatory). Determine presence of unformed (for example sense of presence or fleeting false 
impressions) as well as formed (fully developed and detailed) sensations. Rate the patient’s insight into 
hallucinations and identify delusions and psychotic thinking. 
 
Instructions to patients [and caregiver]: Over the past week have you seen, heard, smelled or felt things 
that were not really there? [If yes, examiner asks patient or caregiver to elaborate and probes for 
information.] 
 
0: Normal: No hallucinations or psychotic behavior. 
 
1: Slight: Illusions or non-formed hallucinations, but patient recognizes them without loss of 
insight. 
 
2: Mild: Formed hallucinations independent of environmental stimuli. No loss of 
insight. 
 
3: Moderate:  Formed hallucinations with loss of insight. 
 
4: Severe:  Patient has delusions or paranoia. 













1.3 DEPRESSED MOOD 
 
Instructions to examiner: Consider low mood, sadness, hopelessness, feelings of emptiness or loss of 
enjoyment. Determine their presence and duration over the past week and rate their interference with 
the patient’s ability to carry out daily routines and engage in social interactions. 
 
Instruction to the patient (and caregiver): Over the past week have you felt low, sad, hopeless or unable 
to enjoy things? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you 
carry out your usual activities or to be with people? [If yes, examiner asks patient or caregiver to 
elaborate and probes for information.] 
 
0: Normal:  No depressed mood. 
 
1: Slight:        Episodes of depressed mood that are not sustained for more than one day at a 
time. No interference with patient’s ability to carry out normal activities and social 
interactions. 
 
2: Mild: Depressed mood that is sustained over days, but without interference with 
normal activities and social interactions. 
 
3: Moderate: Depressed mood that interferes with, but does not preclude, the patient’s ability 
to carry out normal activities and social interactions. 
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1.4 ANXIOUS MOOD 
 
Instructions to examiner: Determine nervous, tense, worried or anxious feelings (including panic attacks) 
over the past week and rate their duration and interference with the patient’s ability to carry out daily 
routines and engage in social interactions. 
 
Instructions to patients [and caregiver]:  Over the past week have you felt nervous, worried or tense? If 
yes, was this feeling for longer than one day at a time? Did it make it difficult for you to follow your usual 
activities or to be with other people? [If yes, examiner asks patient or caregiver to elaborate and probes 
for information.] 
 
0: Normal: No anxious feelings. 
 
1: Slight: Anxious feelings present but not sustained for more than one day at a time. No 
interference with patient’s ability to carry out normal activities and social interactions. 
 
2: Mild: Anxious feelings are sustained over more than one day at a time, but without 
interference with patient’s ability to carry out normal activities and social interactions. 
 
3: Moderate: Anxious feelings interfere with, but do not preclude, the patient’s ability to carry out 
normal activities and social interactions. 
 



















Instructions to examiner: Consider level of spontaneous activity, assertiveness, motivation and initiative 
and rate the impact of reduced levels on performance of daily routines and social interactions. Here the 
examiner should attempt to distinguish between apathy and similar symptoms that are best explained by 
depression. 
 
Instructions to patients (and caregiver): Over the past week, have you felt indifferent to doing activities 
or being with people? [If yes, examiner asks patient or caregiver to elaborate and probes for information.] 
 
0: Normal:      No apathy. 
 
1: Slight: Apathy appreciated by patient and/or caregiver, but no interference with daily 
activities and social interactions. 
 
2: Mild: Apathy interferes with isolated activities and social interactions. 
 
3: Moderate:  Apathy interferes with most activities and social interactions. 
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1.6 FEATURES OF DOPAMINE DYSREGULATION SYNDROME 
 
Instructions to examiner: Consider involvement in a variety of activities including atypical or 
excessive gambling (e.g. casinos or lottery tickets), atypical or excessive sexual drive or 
interests (e.g., unusual interest in pornography, masturbation, sexual demands on partner), 
other repetitive activities (e.g. hobbies, dismantling objects, sorting or organizing), or taking 
extra non-prescribed medication for non-physical reasons (i.e., addictive behavior). Rate the 
impact of such abnormal activities/behaviors on the patient’s personal life and on his family and 
social relations (including need to borrow money or other financial difficulties like withdrawal of 
credit cards, major family conflicts, lost time from work, or missed meals or sleep because of the 
activity). 
 
Instructions to patients [and caregiver]:  Over the past week, have you had unusually strong 
urges that are hard to control? Do you feel driven to do or think about something and find it 
hard to stop? [Give patient examples such as gambling, cleaning, using the computer, taking 
extra medicine, obsessing about food or sex, all depending on the patients.] 




















1: Slight: Problems are present but usually do not cause any difficulties for the patient or  
family/caregiver. 
 
2: Mild: Problems are present and usually cause a few difficulties in the patient’s personal 
and family life. 
 
3: Moderate: Problems are present and usually cause a lot of difficulties in the patient’s personal 
and family life. 
 
4: Severe: Problems are present and preclude the patient’s ability to carry out normal 






















The remaining questions in Part I (Non-motor Experiences of Daily Living) [Sleep, Daytime Sleepiness, Pain and 
Other Sensation, Urinary Problems, Constipation Problems, Lightheadedness on Standing, and Fatigue] are in the 
Patient Questionnaire along with all questions in Part II [Motor Experiences of Daily Living]. 
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This questionnaire will ask you about your experiences of daily living. 
 
There are 20 questions.  We are trying to be thorough, and some of these questions may 
therefore not apply to you now or ever.  If you do not have the problem, simply mark 0 for NO. 
 
Please read each one carefully and read all answers before selecting the one that best 
applies to you. 
 
We are interested in your average or usual function over the past week including today. Some 
patients can do things better at one time of the day than at others. However, only one answer 
is allowed for each question, so please mark the answer that best describes what you can do 
most of the time. 
 
You may have other medical conditions besides Parkinson’s disease.  Do not worry about 
separating Parkinson’s disease from other conditions.  Just answer the question with your 
best response. 
 
Use only 0, 1, 2, 3, 4 for answers, nothing else.  Do not leave any blanks. 
 
Your doctor or nurse can review the questions with you, but this questionnaire is for patients 





Who is filling out this questionnaire (check the best answer): 
 Patient  Caregiver  Patient and Caregiver in Equal Proportion 
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Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) 
 
 
1.7  SLEEP PROBLEMS 
 
Over the past week, have you had trouble going to sleep at night or staying asleep 
through the night? Consider how rested you felt after waking up in the morning. 
 
0: Normal: No problems. 
 
1: Slight: Sleep problems are present but usually do not cause trouble 
getting a full night of sleep. 
 
2: Mild: Sleep problems usually cause some difficulties getting a full night 
of sleep. 
 
3: Moderate: Sleep problems cause a lot of difficulties getting a full night of 
sleep, but I still usually sleep for more than half the night. 
 

















1.8  DAYTIME SLEEPINESS 
 
Over the past week, have you had trouble staying awake during the daytime? 
 
0: Normal: No daytime sleepiness. 
 
1: Slight: Daytime sleepiness occurs but I can resist and I stay awake. 
 
2: Mild: Sometimes I fall asleep when alone and relaxing.  For example, 
while reading or watching TV. 
 
3: Moderate: I sometimes fall asleep when I should not. For example, while 
eating or talking with other people. 
 
4: Severe: I often fall asleep when I should not. For example, while eating or 
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1.9  PAIN AND OTHER SENSATIONS 
 
Over the past week, have you had uncomfortable feelings in your body like pain, aches 
tingling or cramps? 
 
0: Normal: No uncomfortable feelings. 
 
1: Slight: I have these feelings. However, I can do things and be with other 
people without difficulty. 
 
2: Mild: These feelings cause some problems when I do things or am with 
other people. 
 
3: Moderate: These feelings cause a lot of problems, but they do not stop me 
from doing things or being with other people. 
 


















1.10  URINARY PROBLEMS 
 
Over the past week, have you had trouble with urine control?  For example, an urgent 
need to urinate, a need to urinate too often, or urine accidents? 
 
0: Normal: No urine control problems. 
 
1: Slight: I need to urinate often or urgently.  However, these problems do 
not cause difficulties with my daily activities. 
 
2: Mild: Urine problems cause some difficulties with my daily activities. 
However, I do not have urine accidents. 
 
3: Moderate: Urine problems cause a lot of difficulties with my daily activities, 
including urine accidents. 
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1.11  CONSTIPATION PROBLEMS 
 
Over the past week have you had constipation troubles that cause you difficulty 
moving your bowels? 
 
0: Normal: No constipation. 
 
1: Slight: I have been constipated.  I use extra effort to move my bowels. 
However, this problem does not disturb my activities or my being 
comfortable. 
 
2: Mild: Constipation causes me to have some troubles doing things or 
being comfortable. 
 
3: Moderate: Constipation causes me to have a lot of trouble doing things or 
being comfortable.  However, it does not stop me from doing 
anything. 
 

















1.12  LIGHT HEADEDNESS ON STANDING 
 
Over the past week, have you felt faint, dizzy or foggy when you stand up after sitting 
or lying down? 
 
0: Normal: No dizzy or foggy feelings. 
 
1: Slight: Dizzy or foggy feelings occur. However, they do not cause me 
troubles doing things. 
 
2: Mild: Dizzy or foggy feelings cause me to hold on to something, but I do 
not need to sit or lie back down. 
 
3: Moderate:    Dizzy or foggy feelings cause me to sit or lie down to avoid 
fainting or falling. 
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1.13  FATIGUE 
 
Over the past week, have you usually felt fatigued?  This feeling is not part of being 
sleepy or sad. 
 
0: Normal: No fatigue. 
 
1: Slight: Fatigue occurs. However it does not cause me troubles doing 
things or being with people. 
 
2: Mild: Fatigue causes me some troubles doing things or being with 
people. 
 
3: Moderate: Fatigue causes me a lot of troubles doing things or being with 
people.  However, it does not stop me from doing anything. 
 
















Part II: Motor Aspects of Experiences of Daily Living (M-EDL) 
 
 
2.1  SPEECH 
 
Over the past week, have you had problems with your speech? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: My speech is soft, slurred or uneven, but it does not cause others 
to ask me to repeat myself. 
 
2: Mild: My speech causes people to ask me to occasionally repeat 
myself, but not everyday. 
 
3: Moderate: My speech is unclear enough that others ask me to repeat myself 
every day even though most of my speech is understood. 
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2.2 SALIVA AND DROOLING 
 
Over the past week, have you usually had too much saliva during when you are 
awake or when you sleep? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I have too much saliva, but do not drool. 
 
2: Mild: I have some drooling during sleep, but none when I am awake. 
 
3: Moderate: I have some drooling when I am awake, but I usually do not need 
tissues or a handkerchief. 
 
4: Severe: I have so much drooling that I regularly need to use tissues or a 

















2.3  CHEWING AND SWALLOWING 
 
Over the past week, have you usually had problems swallowing pills or eating meals? 
Do you need your pills cut or crushed or your meals to be made soft, chopped or 
blended to avoid choking? 
 
0: Normal: No problems. 
 
1: Slight: I am aware of slowness in my chewing or increased effort at 
swallowing, but I do not choke or need to have my food specially 
prepared. 
 
2: Mild: I need to have my pills cut or my food specially prepared because 
of chewing or swallowing problems, but I have not choked over 
the past week. 
 
3: Moderate. I choked at least once in the past week. 
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2.4  EATING TASKS 
 
Over the past week, have you usually had troubles handling your food and using 
eating utensils?  For example, do you have trouble handling finger foods or using 
forks, knives, spoons, chopsticks? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I am slow, but I do not need any help handling my food and have 
not had food spills while eating. 
 
2: Mild: I am slow with my eating and have occasional food spills.  I may 
need help with a few tasks such as cutting meat. 
 
3: Moderate: I need help with many eating tasks but can manage some alone. 
 

















2.5  DRESSING 
 
Over the past week, have you usually had problems dressing?  For example, are you 
slow or do you need help with buttoning, using zippers, putting on or taking off your 
clothes or jewelry? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I am slow but I do not need help. 
 
2: Mild: I am slow and need help for a few dressing tasks (buttons, 
bracelets). 
 
3: Moderate: I need help for many dressing tasks. 
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2.6  HYGIENE 
 
Over the past week, have you usually been slow or do you need help with washing, 
bathing, shaving, brushing teeth, combing your hair or with other personal hygiene? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I am slow but I do not need any help. 
 
2: Mild: I need someone else to help me with some hygiene tasks. 
 
3: Moderate: I need help for many hygiene tasks. 
 











2.7  HANDWRITING 
 
Over the past week, have people usually had trouble reading your handwriting? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: My writing is slow, clumsy or uneven, but all words are clear. 
 
2: Mild: Some words are unclear and difficult to read. 
 
3: Moderate: Many words are unclear and difficult to read. 
 












2.8  DOING HOBBIES AND OTHER ACTIVITIES 
 
Over the past week, have you usually had trouble doing your hobbies or other things 
that you like to do? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I am a bit slow but do these activities easily. 
 
2: Mild: I have some difficulty doing these activities. 
 
3: Moderate: I have major problems doing these activities, but still do most. 
 










July 1, 2008 Page 15 Copyright © 2008 International Parkinson and Movement Disorder Society. All rights reserved 





2.9  TURNING IN BED 
 
Over the past week, do you usually have trouble turning over in bed? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I have a bit of trouble turning, but I do not need any help. 
 
2: Mild I have a lot of trouble turning and need occasional help from 
someone else. 
 
3: Moderate: To turn over I often need help from someone else. 
 











2.10  TREMOR 
 
Over the past week, have you usually had shaking or tremor? 
 
0: Normal: Not at all. I have no shaking or tremor. 
 
1: Slight: Shaking or tremor occurs but does not cause problems with any 
activities. 
 
2: Mild: Shaking or tremor causes problems with only a few activities. 
 
3: Moderate: Shaking or tremor causes problems with many of my daily 
activities. 
 












2.11  GETTING OUT OF BED, A CAR, OR A DEEP CHAIR 
 
Over the past week, have you usually had trouble getting out of bed, a car seat, or a 
deep chair? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I am slow or awkward, but I usually can do it on my first try. 
 
2: Mild: I need more than one try to get up or need occasional help. 
 
3: Moderate: I sometimes need help to get up, but most times I can still do it on 
my own. 
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2.12  WALKING AND BALANCE 
 
Over the past week, have you usually had problems with balance and walking? 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I am slightly slow or may drag a leg. I never use a walking aid. 
 
2: Mild: I occasionally use a walking aid, but I do not need any help from 
another person. 
 
3: Moderate: I usually use a walking aid (cane, walker) to walk safely without 
falling. However, I do not usually need the support of another 
person. 
 














2.13  FREEZING 
 
Over the past week, on your usual day when walking, do you suddenly stop or freeze 
as if your feet are stuck to the floor. 
 
0: Normal: Not at all (no problems). 
 
1: Slight: I briefly freeze but I can easily start walking again. I do not need 
help from someone else or a walking aid (cane or walker) because 
of freezing. 
 
2: Mild: I freeze and have trouble starting to walk again, but I do not need 
someone’s help or a walking aid (cane or walker) because of 
freezing. 
 
3: Moderate: When I freeze I have a lot of trouble starting to walk again and, 
because of freezing, I sometimes need to use a walking aid or 
need someone else’s help. 
 
4: Severe: Because of freezing, most or all of the time, I need to use a 

















This completes the questionnaire.  We may have asked about problems you do not even have, 
and may have mentioned problems that you may never develop at all.  Not all patients develop all 
these problems, but because they can occur, it is important to ask all the questions to every 
patient. Thank you for your time and attention in completing this questionnaire. 
July 1, 2008 Page 17 Copyright © 2008 International Parkinson and Movement Disorder Society. All rights reserved 
This scale may not be copied, distributed or otherwise used in whole or in part without prior written consent of the International Parkinson and Movement Disorder Society 
 




Overview: This portion of the scale assesses the motor signs of PD. In administering Part III of the MDS-UPDRS 
the examiner should comply with the following guidelines: 
 
At the top of the form, mark whether the patient is on medication for treating the symptoms of Parkinson's disease 
and, if on levodopa, the time since the last dose. 
 
Also, if the patient is receiving medication for treating the symptoms of Parkinson’s Disease, mark the patient’s 
clinical state using the following definitions: 
ON is the typical functional state when patients are receiving medication and have a good response. 
OFF is the typical functional state when patients have a poor response in spite of taking medications. 
 
The investigator should “rate what you see”. Admittedly, concurrent medical problems such as stroke, paralysis, 
arthritis, contracture, and orthopedic problems such as hip or knee replacement and scoliosis may interfere with 
individual items in the motor examination. In situations where it is absolutely impossible to test (e.g., amputations, 
plegia, limb in a cast), use the notation “UR” for Unable to Rate. Otherwise, rate the performance of each task as the 
patient performs in the context of co-morbidities. 
 
All items must have an integer rating (no half points, no missing ratings). 
 
Specific instructions are provided for the testing of each item. These should be followed in all instances. The 
investigator demonstrates while describing tasks the patient is to perform and rates function immediately thereafter. 
For Global Spontaneous Movement and Rest Tremor items (3.14 and 3.17), these items have been placed 
purposefully at the end of the scale because clinical information pertinent to the score will be obtained throughout the 
entire examination. 
 
At the end of the rating, indicate if dyskinesia (chorea or dystonia) was present at the time of the examination, and if 














3b If the patient is receiving medication for treating the symptoms of Parkinson’s Disease, 
mark the patient’s clinical state using the following definitions: 
 
 ON: On is the typical functional state when patients are receiving medication and have a good response. 
 




3c  Is the patient on Levodopa ?  No  Yes 
 
3.C1 If yes, minutes since last levodopa dose:     
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Instructions to examiner: Listen to the patient’s free-flowing speech and engage in conversation if 
necessary. Suggested topics: ask about the patient’s work, hobbies, exercise, or how he got to the 
doctor’s office. Evaluate volume, modulation (prosody) and clarity, including slurring, palilalia (repetition 
of syllables) and tachyphemia (rapid speech, running syllables together). 
 
0: Normal: No speech problems. 
 
1: Slight: Loss of modulation, diction or volume, but still all words easy to understand. 
 
2: Mild: Loss of modulation, diction, or volume, with a few words unclear, but the overall 
sentences easy to follow. 
 
3: Moderate:  Speech is difficult to understand to the point that some, but not most, sentences are 
poorly understood. 
 
















3.2 FACIAL EXPRESSION 
 
Instructions to examiner: Observe the patient sitting at rest for 10 seconds, without talking and also 
while talking. Observe eye-blink frequency, masked facies or loss of facial expression, spontaneous 
smiling and parting of lips. 
 
0: Normal: Normal facial expression. 
 
1: Slight: Minimal masked facies manifested only by decreased frequency of blinking. 
 
2: Mild: In addition to decreased eye-blink frequency, Masked facies present in the lower 
face as well, namely fewer movements around the mouth, such as less 
spontaneous smiling, but lips not parted. 
 
3: Moderate:   Masked facies with lips parted some of the time when the mouth is at rest. 
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Instructions to examiner: Rigidity is judged on slow passive movement of major joints with the patient in 
a relaxed position and the examiner manipulating the limbs and neck. First, test without an activation 
maneuver. Test and rate neck and each limb separately. For arms, test the wrist and elbow joints 
simultaneously. For legs, test the hip and knee joints simultaneously. If no rigidity is detected, use an 
activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being 
tested. Explain to the patient to go as limp as possible as you test for rigidity. 
 
0: Normal: No rigidity. 
 
1: Slight: Rigidity only detected with activation maneuver. 
 
2: Mild: Rigidity detected without the activation maneuver, but full range of motion is easily 
achieved. 
 
3: Moderate:   Rigidity detected without the activation maneuver; full range of motion is achieved 
with effort. 
 













3.4 FINGER TAPPING 
 
Instructions to examiner: Each hand is tested separately. Demonstrate the task, but do not continue to 
perform the task while the patient is being tested.  Instruct the patient to tap the index finger on the 
thumb 10 times as quickly AND as big as possible.  Rate each side separately, evaluating speed, 
amplitude, hesitations, halts and decrementing amplitude. 
 
0: Normal: No problems. 
 
1: Slight:        Any of the following: a) the regular rhythm is broken with one or two interruptions or 
hesitations of the tapping movement; b) slight slowing; c) the amplitude decrements 
near the end of the 10 taps. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during tapping; b) mild slowing; c) the 
amplitude decrements midway in the 10-tap sequence. 
 
3: Moderate:   Any of the following: a) more than 5 interruptions during tapping or at least one 
longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the amplitude 
decrements starting after the 1st tap. 
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3.5 HAND MOVEMENTS 
 
Instructions to examiner: Test each hand separately. Demonstrate the task, but do not continue to 
perform the task while the patient is being tested. Instruct the patient to make a tight fist with the arm 
bent at the elbow so that the palm faces the examiner. Have the patient open the hand 10 times as fully 
AND as quickly as possible. If the patient fails to make a tight fist or to open the hand fully, remind him/ 
her to do so. Rate each side separately, evaluating speed, amplitude, hesitations, halts and 
decrementing amplitude. 
 
0: Normal: No problem. 
 
1: Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or 
hesitations of the movement; b) slight slowing; c) the amplitude decrements near 
the end of the task. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild slowing; 
c) the amplitude decrements midway in the task. 
 
3: Moderate:   Any of the following: a) more than 5 interruptions during the movement or at least 
one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the 
amplitude decrements starting after the 1st open-and-close sequence. 
 
















3.6  PRONATION-SUPINATION MOVEMENTS OF HANDS 
 
Instructions to examiner: Test each hand separately. Demonstrate the task, but do not continue to 
perform the task while the patient is being tested. Instruct the patient to extend the arm out in front of 
his/her body with the palms down; then to turn the palm up and down alternately 10 times as fast and as 
fully as possible. Rate each side separately, evaluating speed, amplitude, hesitations, halts and 
decrementing amplitude. 
 
0: Normal:       No problems. 
 
1: Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or 
hesitations of the movement; b) slight slowing; c) the amplitude decrements near 
the end of the sequence. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild slowing; 
c) the amplitude decrements midway in the sequence. 
 
3: Moderate:   Any of the following: a) more than 5 interruptions during the movement or at least 
one longer arrest (freeze) in ongoing movement; b) moderate slowing c) the 
amplitude decrements starting after the 1st supination-pronation sequence. 
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3.7 TOE TAPPING 
 
Instructions to examiner: Have the patient sit in a straight-backed chair with arms, both feet on the floor. 
Test each foot separately. Demonstrate the task, but do not continue to perform the task while the 
patient is being tested. Instruct the patient to place the heel on the ground in a comfortable position and 
then tap the toes 10 times as big and as fast as possible. Rate each side separately, evaluating speed, 
amplitude, hesitations, halts and decrementing amplitude. 
 
0:   Normal: No problem. 
 
1: Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions 
or hesitations of the tapping movement; b) slight slowing; c) amplitude 
decrements near the end of the ten taps. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during the tapping movements; b) mild 
slowing; c) amplitude decrements midway in the task. 
 
3: Moderate: Any of the following: a) more than 5 interruptions during the tapping movements 
or at least one longer arrest (freeze) in ongoing movement; b) moderate slowing; 
c) amplitude decrements after the first tap. 
 
















3.8 LEG AGILITY 
 
Instructions to examiner: Have the patient sit in a straight-backed chair with arms. The patient should 
have both feet comfortably on the floor. Test each leg separately. Demonstrate the task, but do not 
continue to perform the task while the patient is being tested. Instruct the patient to place the foot on the 
ground in a comfortable position and then raise and stomp the foot on the ground 10 times as high and 
as fast as possible. Rate each side separately, evaluating speed, amplitude, hesitations, halts and 
decrementing amplitude. 
 
0: Normal: No problems. 
 
1: Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions 
or hesitations of the movement; b) slight slowing; c) amplitude decrements near 
the end of the task. 
 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild 
slowness; c) amplitude decrements midway in the task. 
 
3: Moderate:     Any of the following: a) more than 5 interruptions during the movement or at 
least one longer arrest (freeze) in ongoing movement; b) moderate slowing in 
speed; c) amplitude decrements after the first tap. 
 
4: Severe:     Cannot or can only barely perform the task because of slowing, interruptions        
















July 1, 2008 Page 22 Copyright © 2008 International Parkinson and Movement Disorder Society. All rights reserved 




3.9 ARISING FROM CHAIR 
 
Instructions to examiner: Have the patient sit in a straight-backed chair with arms, with both feet on the 
floor and sitting back in the chair (if the patient is not too short). Ask the patient to cross his/her arms 
across the chest and then to stand up. If the patient is not successful, repeat this attempt a maximum up 
to two more times. If still unsuccessful, allow the patient to move forward in the chair to arise with arms 
folded across the chest. Allow only one attempt in this situation. If unsuccessful, allow the patient to 
push off using his/her hands on the arms of the chair. Allow a maximum of three trials of pushing off. If 
still not successful, assist the patient to arise. After the patient stands up, observe the posture for item 
3.13. 
 
0: Normal: No problems. Able to arise quickly without hesitation. 
 
1: Slight:              Arising is slower than normal; or may need more than one attempt; or may 
need to move forward in the chair to arise. No need to use the arms of the 
chair. 
 
2: Mild: Pushes self up from arms of chair without difficulty. 
 
3: Moderate: Needs to push off, but tends to fall back; or may have to try more than one time 
using arms of chair, but can get up without help. 
 


















Instructions to examiner: Testing gait is best performed by having the patient walking away from and 
towards the examiner so that both right and left sides of the body can be easily observed 
simultaneously. The patient should walk at least 10 meters (30 feet), then turn around and return to 
the examiner. This item measures multiple behaviors: stride amplitude, stride speed, height of foot lift, 
heel strike during walking, turning, and arm swing, but not freezing. Assess also for “freezing of gait” 
(next item 3.11) while patient is walking. Observe posture for item 3.13. 
 
0: Normal: No problems. 
 
1: Slight: Independent walking with minor gait impairment. 
 
2: Mild: Independent walking but with substantial gait impairment. 
 
3: Moderate: Requires an assistance device for safe walking (walking stick, walker) but not a 
person. 
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3.11 FREEZING OF GAIT 
 
Instructions to examiner:  While assessing gait, also assess for the presence of any gait freezing 
episodes. Observe for start hesitation and stuttering movements especially when turning and reaching 
the end of the task. To the extent that safety permits, patients may NOT use sensory tricks during the 
assessment. 
 
0: Normal: No freezing. 
 
1: Slight:            Freezes on starting, turning or walking through doorway with a single halt during 
any of these events, but then continues smoothly without freezing during straight 
walking. 
 
2: Mild:  Freezes on starting, turning or walking through doorway with more than one halt 
during any of these activities, but continues smoothly without freezing during 
straight walking. 
 
3: Moderate: Freezes once during straight walking. 
 














3.12 POSTURAL STABILITY 
 
Instructions to examiner: The test examines the response to sudden body displacement produced by a 
quick, forceful pull on the shoulders while the patient is standing erect with eyes open and feet 
comfortably apart and parallel to each other. Test retropulsion. Stand behind the patient and instruct 
the patient on what is about to happen. Explain that s/he is allowed to take a step backwards to avoid 
falling. There should be a solid wall behind the examiner, at least 1-2 meters away to allow for the 
observation of the number of retropulsive steps. The first pull is an instructional demonstration and is 
purposely milder and not rated. The second time the shoulders are pulled briskly and forcefully towards 
the examiner with enough force to displace the center of gravity so that patient MUST take a step 
backwards. The examiner needs to be ready to catch the patient, but must stand sufficiently back so as 
to allow enough room for the patient to take several steps to recover independently. Do not allow the 
patient to flex the body abnormally forward in anticipation of the pull. Observe for the number of steps 
backwards or falling. Up to and including two steps for recovery is considered normal, so abnormal 
ratings begin with three steps. If the patient fails to understand the test, the examiner can repeat the 
test so that the rating is based on an assessment that the examiner feels reflects the patient’s limitations 
rather than misunderstanding or lack of preparedness. Observe standing posture for item 3.13 
 
0: Normal: No problems: Recovers with one or two steps. 
 
1: Slight: 3-5 steps, but subject recovers unaided. 
 
2: Mild: More than 5 steps, but subject recovers unaided. 
 
3: Moderate: Stands safely, but with absence of postural response; falls if not caught by 
examiner. 
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Instructions to examiner: Posture is assessed with the patient standing erect after arising from a chair, 
during walking, and while being tested for postural reflexes. If you notice poor posture, tell the patient 
to stand up straight and see if the posture improves (see option 2 below). Rate the worst posture seen 
in these three observation points. Observe for flexion and side-to-side leaning. 
 
0: Normal: No problems. 
 
1: Slight: Not quite erect, but posture could be normal for older person. 
 
2: Mild: Definite flexion, scoliosis or leaning to one side, but patient can correct posture 
to normal posture when asked to do so. 
 
3:  Moderate: Stooped posture, scoliosis or leaning to one side that cannot be corrected 
volitionally to a normal posture by the patient. 
 











3.14 GLOBAL SPONTANEITY OF MOVEMENT (BODY BRADYKINESIA) 
 
Instructions to examiner: This global rating combines all observations on slowness, hesitancy, and 
small amplitude and poverty of movement in general, including a reduction of gesturing and of crossing 
the legs. This assessment is based on the examiner’s global impression after observing for 
spontaneous gestures while sitting, and the nature of arising and walking. 
 
0: Normal: No problems. 
 
1: Slight: Slight global slowness and poverty of spontaneous movements. 
 
2: Mild: Mild global slowness and poverty of spontaneous movements. 
 
3: Moderate: Moderate global slowness and poverty of spontaneous movements. 
 










3.15 POSTURAL TREMOR OF THE HANDS 
 
 Instructions to examiner: All tremor, including re-emergent rest tremor, that is present in this posture is 
to be included in this rating. Rate each hand separately. Rate the highest amplitude seen. Instruct the 
patient to stretch the arms out in front of the body with palms down. The wrist should be straight and 
the fingers comfortably separated so that they do not touch each other. Observe this posture for 10 
seconds. 
 
0: Normal: No tremor. 
 
1: Slight: Tremor is present but less than 1 cm in amplitude. 
 
2: Mild: Tremor is at least 1 but less than 3 cm in amplitude. 
 
3: Moderate: Tremor is at least 3 but less than 10 cm in amplitude. 
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3.16 KINETIC TREMOR OF THE HANDS 
 
Instructions to examiner: This is tested by the finger-to-nose maneuver. With the arm starting from the 
outstretched position, have the patient perform at least three finger-to-nose maneuvers with each hand 
reaching as far as possible to touch the examiner’s finger. The finger-to-nose maneuver should be 
performed slowly enough not to hide any tremor that could occur with very fast arm movements. Repeat 
with the other hand, rating each hand separately. The tremor can be present throughout the movement 
or as the tremor reaches either target (nose or finger). Rate the highest amplitude seen. 
 
0: Normal: No tremor. 
 
1: Slight: Tremor is present but less than 1 cm in amplitude. 
 
2: Mild: Tremor is at least 1 but less than 3 cm in amplitude. 
 
3: Moderate: Tremor is at least 3 but less than 10 cm in amplitude. 
 













3.17  REST TREMOR AMPLITUDE 
 
Instructions to examiner: This and the next item have been placed purposefully at the end of the 
examination to allow the rater to gather observations on rest tremor that may appear at any time during 
the exam, including when quietly sitting, during walking and during activities when some body parts are 
moving but others are at rest. Score the maximum amplitude that is seen at any time as the final score. 
Rate only the amplitude and not the persistence or the intermittency of the tremor. 
As part of this rating, the patient should sit quietly in a chair with the hands placed on the arms of the 
chair (not in the lap) and the feet comfortably supported on the floor for 10 seconds with no other 
directives. Rest tremor is assessed separately for all four limbs and also for the lip/jaw. Rate only the 




0: Normal: No tremor. 
 
1: Slight: ≤ 1 cm in maximal amplitude. 
 
2: Mild: > 1 cm but < 3 cm in maximal amplitude. 
 
3: Moderate: 3 - 10 cm in maximal amplitude. 
 






0: Normal: No tremor. 
 
1: Slight: ≤ 1 cm in maximal amplitude. 
 
2: Mild: > 1 cm but ≤ 2 cm in maximal amplitude. 
 
3: Moderate: > 2 cm but ≤ 3 cm in maximal amplitude. 
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3.18 CONSTANCY OF REST TREMOR 
 
Instructions to examiner: This item receives one rating for all rest tremor and focuses on the constancy 
of rest tremor during the examination period when different body parts are variously at rest. It is rated 
purposefully at the end of the examination so that several minutes of information can be coalesced into 
the rating. 
 
0: Normal: No tremor. 
 
1: Slight: Tremor at rest is present ≤ 25% of the entire examination period. 
 
2: Mild: Tremor at rest is present 26-50% of the entire examination period. 
 
3: Moderate: Tremor at rest is present 51-75% of the entire examination period. 
 













DYSKINESIA IMPACT ON PART III RATINGS 
 
A. Were dyskinesias (chorea or dystonia) present during examination?   No   Yes 
 




HOEHN AND YAHR STAGE 
 
0:  Asymptomatic. 
 
1:  Unilateral involvement only. 
 
2:  Bilateral involvement without impairment of balance. 
 
3:  Mild to moderate involvement; some postural instability but physically independent; needs 
assistance to recover from pull test. 
 
4:  Severe disability; still able to walk or stand unassisted. 
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Part IV: Motor Complications 
 
 
Overview and Instructions: In this section, the rater uses historical and objective information to assess two motor 
complications, dyskinesias and motor fluctuations that include OFF-state dystonia. Use all information from patient, 
caregiver, and the examination to answer the six questions that summarize function over the past week including 
today. As in the other sections, rate using only integers (no half points allowed) and leave no missing ratings. If the 
item cannot be rated, place UR for Unable to Rate. You will need to choose some answers based on percentages, 
and therefore you will need to establish how many hours generally are awake hours and use this figure as the 
denominator for “OFF” time and dyskinesias. For “OFF dystonia”, the total “Off” time will be the denominator. 
Operational definitions for examiner’s use. 
 
Dyskinesias: Involuntary random movements 
Words that patients often recognize for dyskinesias include “irregular jerking”, “wiggling”, “twitching”. It is essential to 
stress to the patient the difference between dyskinesias and tremor, a common error when patients are assessing 
dyskinesias. 
 
Dystonia: contorted posture, often with a twisting component: 
Words that patients often recognize for dystonia include “spasms”, “cramps”, “posture”. 
 
Motor fluctuation: Variable response to medication: 
Words that patients often recognize for motor fluctuation include “wearing out”, “wearing off”, “roller-coaster effect”, 
“on-off”, “uneven medication effects”. 
 
OFF: Typical functional state when patients have a poor response in spite of taking mediation or the typical functional 
response when patients are on NO treatment for parkinsonism. Words that patients often recognize include “low 
time”, “bad time”, “shaking time”, “slow time”, “time when my medications don’t work.” 
 
ON: Typical functional state when patients are receiving medication and have a good response: 
Words that patients often recognize include “good time”, “walking time”, “time when my medications work.” 
 
A. DYSKINESIAS [exclusive of OFF-state dystonia] 
 
                                                                                                                                                         SCORE 
4.1 TIME SPENT WITH DYSKINESIAS  
 
Instructions to examiner:  Determine the hours in the usual waking day and then the hours of 
dyskinesias. Calculate the percentage. If the patient has dyskinesias in the office, you can point them 
out as a reference to ensure that patients and caregivers understand what they are rating. You may also 
use your own acting skills to enact the dyskinetic movements you have seen in the patient before or 
show them dyskinetic movements typical of other patients. Exclude from this question early morning 
and nighttime painful dystonia. 
 
Instructions to patient [and caregiver]: Over the past week, how many hours do you usually sleep on a 
daily basis, including nighttime sleep and daytime napping? Alright, if you sleep ___ hrs, you are awake 
____ hrs. Out of those awake hours, how many hours in total do you have wiggling, twitching or jerking 
movements? Do not count the times when you have tremor, which is a regular back and forth shaking 
or times when you have painful foot cramps or spasms in the early morning or at nighttime. I will ask 
about those later. Concentrate only on these types of wiggling, jerking and irregular movements. Add 
up all the time during the waking day when these usually occur. How many hours ____ (use this 
number for your calculations). 
 
























> 75% of waking day. 
 
 
3. % Dyskinesia = ((2/1)*100):    
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Total Hours Awake: 
 




Total Hours OFF: 
 




% OFF = ((2/1)*100): 
 
   
 
 
4.2 FUNCTIONAL IMPACT OF DYSKINESIAS 
 
Instructions to examiner:  Determine the degree to which dyskinesias impact on the patient’s daily 
function in terms of activities and social interactions. Use the patient’s and caregiver’s response to your 
 question and your own observations during the office visit to arrive at the best answer. 
 
Instructions to patient [and caregiver]: Over the past week, did you usually have trouble doing things or 
being with people when these jerking movements occurred? Did they stop you from doing things or 
from being with people? 
 
0: Normal: No dyskinesias or no impact by dyskinesias on activities or social interactions. 
 
1: Slight: Dyskinesias impact on a few activities, but the patient usually performs all 
activities and participates in all social interactions during dyskinetic periods. 
 
2: Mild: Dyskinesias impact on many activities, but the patient usually performs all 
activities and participates in all social interactions during dyskinetic periods. 
 
3: Moderate: Dyskinesias impact on activities to the point that the patient usually does not 
perform some activities or does not usually participate in some social activities 
during dyskinetic episodes. 
 
4: Severe: Dyskinesias impact on function to the point that the patient usually does not 


















B. MOTOR FLUCTUATIONS 
 
 
4.3 TIME SPENT IN THE OFF STATE 
 
Instructions to examiner: Use the number of waking hours derived from 4.1 and determine the hours 
spent in the “OFF” state. Calculate the percentage. If the patient has an OFF period in the office, you 
can point to this state as a reference. You may also use your knowledge of the patient to describe a 
typical OFF period. Additionally you may use your own acting skills to enact an OFF period you have 
seen in the patient before or show them OFF function typical of other patients. Mark down the typical 
number of OFF hours, because you will need this number for completing 4.6. 
 
Instructions to patient [and caregiver]: Some patients with Parkinson’s disease have a good effect from 
their medications throughout their awake hours and we call that “ON” time. Other patients take their 
medications but still have some hours of low time, bad time, slow time or shaking time. Doctors call these 
low periods “OFF” time. Over the past week, you told me before that you are general awake ____ hrs 
each day. Out of these awake hours, how many hours in total do you usually have this type of low level 
or OFF function ____ (use this number for your calculations).
 
0: Normal: No OFF time. 
 
1: Slight: ≤ 25% of waking day. 
 
2: Mild: 26 - 50% of waking day. 
 
3: Moderate: 51 - 75% of waking day. 
 
4: Severe: > 75% of waking day. 
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4.4 FUNCTIONAL IMPACT OF FLUCTUATIONS 
 
Instructions to examiner:  Determine the degree to which motor fluctuations impact on the patient’s daily 
function in terms of activities and social interactions. This question concentrates on the difference 
between the ON state and the OFF state. If the patient has no OFF time, the rating must be 0, but if 
patients have very mild fluctuations, it is still possible to be rated 0 on this item if no impact on activities 
occurs. Use the patient’s and caregiver’s response to your question and your own observations during 
the office visit to arrive at the best answer. 
 
Instructions to patient [and caregiver]: Think about when those low or “OFF” periods have occurred over 
the past week. Do you usually have more problems doing things or being with people than compared to 
the rest of the day when you feel your medications working? Are there some things you usually do 
during a good period that you have trouble with or stop doing during a low period? 
 
0: Normal: No fluctuations or No impact by fluctuations on performance of activities or 
social interactions. 
 
1: Slight: Fluctuations impact on a few activities, but during OFF, the patient usually 
performs all activities and participates in all social interactions that typically 
occur during the ON state. 
 
2: Mild:                  Fluctuations impact many activities, but during OFF, the patient still usually 
performs all activities and participates in all social interactions that typically 
occur during the ON state. 
 
3: Moderate: Fluctuations impact on the performance of activities during OFF to the point that 
the patient usually does not perform some activities or participate in some 
social interactions that are performed during ON periods. 
 
4: Severe: Fluctuations impact on function to the point that, during OFF, the patient usually 
does not perform most activities or participate in most social interactions that 



















4.5 COMPLEXITY OF MOTOR FLUCTUATIONS 
 
Instructions to examiner:  Determine the usual predictability of OFF function whether due to dose, time 
of day, food intake or other factors. Use the information provided by the patients and caregiver and 
supplement with your own observations. You will ask if the patient can count on them always coming at 
a special time, mostly coming at a special time (in which case you will probe further to separate slight 
from mild), only sometimes coming at a special time  or are they totally unpredictable?  Narrowing down 
the percentage will allow you to find the correct answer. 
 
Instructions to patient [and caregiver]:  For some patients, the low or “OFF” periods happen at certain 
times during day or when they do activities like eating or exercising. Over the past week, do you usually 
know when your low periods will occur? In other words, do your low periods always come at a certain 
time? Do they mostly come at a certain time? Do they only sometimes come at a certain time? Are 
your low periods totally unpredictable?” 
 
0: Normal: No motor fluctuations. 
 
1: Slight: OFF times are predictable all or almost all of the time (> 75%). 
 
2: Mild: OFF times are predictable most of the time (51-75%). 
 
3: Moderate: OFF times are predictable some of the time (26-50%). 
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C. “OFF” DYSTONIA 
 
4.6 PAINFUL OFF-STATE DYSTONIA 
 
Instructions to examiner: For patients who have motor fluctuations, determine what proportion of the 
OFF episodes usually includes painful dystonia? You have already determined the number of hours of 
“OFF” time (4.3). Of these hours, determine how many are associated with dystonia and calculate the 
percentage. If there is no OFF time, mark 0. 
 
Instructions to patient [and caregiver]:  In one of the questions I asked earlier, you said you generally 
have ____ hours of low or “OFF” time when your Parkinson's disease is under poor control. During 
these low or “OFF” periods, do you usually have painful cramps or spasms? Out of the total ____ hrs of 
this low time, if you add up all the time in a day when these painful cramps come, how many hours would 
this make? 
 
0: Normal: No dystonia OR NO OFF TIME. 
 
1: Slight: ≤ 25% of time in OFF state. 
 
2: Mild: 26-50% of time in OFF state. 
 
3: Moderate: 51-75% of time in OFF state. 
 















 1. Total Hours Off: 
 
2.  Total Off Hours w/Dystonia:    
 













Summary statement to patient: READ TO PATIENT 
 
This completes my rating of your Parkinson’s disease.  I know the questions and tasks have taken several minutes, 
but I wanted to be complete and cover all possibilities. In doing so, I may have asked about problems you do not 
even have, and I may have mentioned problems that you may never develop at all. Not all patients develop all these 
problems, but because they can occur, it is important to ask all the questions to every patient. Thank you for your 
time and attention in completing this scale with me. 
 
























Source of information 
Patient 
Caregiver 
Patient + Caregiver 




Rigidity– LUE  
Part I 3.3d Rigidity– RLE  
1.1 Cognitive impairment  3.3e Rigidity– LLE  
1.2 Hallucinations and psychosis  3.4a Finger tapping– Right hand  
1.3 Depressed mood  3.4b Finger tapping– Left hand  
1.4 Anxious mood  3.5a Hand movements– Right hand  
1.5 Apathy  3.5b Hand movements– Left hand  
1.6 Features of DDS  3.6a Pronation- supination movements– Right hand  
1.6a   Who is filling out questionnaire 
          Patient 
          Caregiver 
          Patient + Caregiver 
3.6b   Pronation- supination movements– Left hand  
3.7a   Toe tapping– Right foot  
1.7 Sleep problems  3.7b Toe tapping– Left foot  
1.8 Daytime sleepiness  3.8a Leg agility– Right leg  
1.9 Pain and other sensations  3.8b Leg agility– Left leg  
1.10 Urinary problems     3.9 Arising from chair  
1.11 Constipation problems  3.10 Gait  
1.12 Light headedness on standing  3.11 Freezing of gait  
1.13 Fatigue  3.12 Postural stability  
Part II 3.13 Posture  
2.1 Speech  3.14 Global spontaneity of movement  
2.2 Saliva and drooling  3.15a Postural tremor– Right hand  
2.3 Chewing and swallowing  3.15b Postural tremor– Left hand  
2.4 Eating tasks  3.16a Kinetic tremor– Right hand  
2.5 Dressing  3.16b Kinetic tremor– Left hand  
2.6 Hygiene  3.17a Rest tremor amplitude– RUE  
2.7 Handwriting  3.17b Rest tremor amplitude– LUE  
2.8 Doing hobbies and other activities  3.17c Rest tremor amplitude– RLE  
2.9 Turning in bed  3.17d Rest tremor amplitude– LLE  
2.10 Tremor  3.17e Rest tremor amplitude– Lip/jaw  




Walking and balance   
 






Freezing   
 
Did these movements interfere with ratings? 
 
No Yes 
3a   Is the patient on medication?          No            Yes    Hoehn and Yahr Stage 
 




Is the patient on Levodopa?               No   Yes 4.1 
 
Time spent with dyskinesias  
3.C1 If yes, minutes since last dose:  4.2 Functional impact of dyskinesias  
Part III 4.3 Time spent in the OFF state  
3.1 Speech  4.4 Functional impact of fluctuations  
3.2 Facial expression  4.5 Complexity of motor fluctuations  
3.3a Rigidity– Neck  4.6 Painful OFF-state dystonia  
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Rating Clinician-rated
Administration time 10–15 minutes
Main purpose To assess the severity of symptoms
of anxiety
Population Adults, adolescents and children
Commentary 
The HAM-A was one of the first rating scales developed
to measure the severity of anxiety symptoms, and is still
widely used today in both clinical and research settings.
The scale consists of 14 items, each defined by a series of
symptoms, and measures both psychic anxiety (mental
agitation and psychological distress) and somatic anxiety
(physical complaints related to anxiety). Although the
HAM-A remains widely used as an outcome measure in
clinical trials, it has been criticized for its sometimes poor
ability to discriminate between anxiolytic and antidepres-
sant effects, and somatic anxiety versus somatic side
effects.  The HAM-A does not provide any standardized
probe questions. Despite this, the reported levels of inter-
rater reliability for the scale appear to be acceptable. 
Scoring 
Each item is scored on a scale of 0 (not present) to 4
(severe), with a total score range of 0–56, where <17 indi-
cates mild severity, 18–24 mild to moderate severity and
25–30 moderate to severe.
Versions 
The scale has been translated into: Cantonese for China,
French and Spanish. An IVR version of the scale is avail-
able from Healthcare Technology Systems.
Additional references 
Maier W, Buller R, Philipp M, Heuser I. The Hamilton
Anxiety Scale: reliability, validity and sensitivity to
change in anxiety and depressive disorders. J Affect
Disord 1988;14(1):61–8. 
Borkovec T and Costello E. Efficacy of applied
relaxation and cognitive behavioral therapy in the
treatment of generalized anxiety disorder. J Clin
Consult Psychol 1993; 61(4):611–19
Address for correspondence 
The HAM-A is in the public domain.
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Hamilton Anxiety Rating Scale (HAM-A)
Reference: Hamilton M.The assessment of anxiety states by rating. Br J Med Psychol 1959;
32:50–55.
82
Below is a list of phrases that describe certain feeling that people have. Rate the patients by finding the answer which best describes the extent
to which he/she has these conditions. Select one of the five responses for each of the fourteen questions.
0 = Not present, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very severe.
Hamilton Anxiety Rating Scale (HAM-A)
! ! ! ! ! ! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
! ! ! ! !
1 Anxious mood 0 1 2 3 4
Worries, anticipation of the worst, fearful anticipation, irritability.
2 Tension 0 1 2 3 4
Feelings of tension, fatigability, startle response, moved to tears
easily, trembling, feelings of restlessness, inability to relax.
3 Fears 0 1 2 3 4
Of dark, of strangers, of being left alone, of animals, of traffic, of
crowds.
4 Insomnia 0 1 2 3 4
Difficulty in falling asleep, broken sleep, unsatisfying sleep and fatigue
on waking, dreams, nightmares, night terrors.
5 Intellectual 0 1 2 3 4
Difficulty in concentration, poor memory.
6 Depressed mood 0 1 2 3 4
Loss of interest, lack of pleasure in hobbies, depression, early waking,
diurnal swing.
7 Somatic (muscular) 0 1 2 3 4
Pains and aches, twitching, stiffness, myoclonic jerks, grinding of
teeth, unsteady voice, increased muscular tone.
8 Somatic (sensory) 0 1 2 3 4
Tinnitus, blurring of vision, hot and cold flushes, feelings of weakness,
pricking sensation.
9 Cardiovascular symptoms 0 1 2 3 4
Tachycardia, palpitations, pain in chest, throbbing of vessels, fainting
feelings, missing beat.
10 Respiratory symptoms 0 1 2 3 4
Pressure or constriction in chest, choking feelings, sighing, dyspnea.
11 Gastrointestinal symptoms 0 1 2 3 4
Difficulty in swallowing, wind abdominal pain, burning sensations,
abdominal fullness, nausea, vomiting, borborygmi, looseness of
bowels, loss of weight, constipation.
12 Genitourinary symptoms 0 1 2 3 4
Frequency of micturition, urgency of micturition, amenorrhea,
menorrhagia, development of frigidity, premature ejaculation, loss of
libido, impotence.
13 Autonomic symptoms 0 1 2 3 4
Dry mouth, flushing, pallor, tendency to sweat, giddiness, tension
headache, raising of hair.
14 Behavior at interview 0 1 2 3 4
Fidgeting, restlessness or pacing, tremor of hands, furrowed brow,






1.   Depressed Mood      
      (sadness, hopeless, helpless, worthless) 
0     Absent 
1     These feeling states indicated only on questioning 
2     These feeling states spontaneously reported verbally 
3     Communicates feeling states nonverbally, i.e., through facial  
        expression, posture, voice and tendency to weep 
4      Patient reports VIRTUALLY ONLY these feeling states in his  
    spontaneous verbal and nonverbal communication 
 
2. Feelings of Guilt 
0     Absent 
1     Self-reproach, feels he has let people down 
2 Ideas of guilt or rumination over past errors or sinful deeds 
3 Present illness is a punishment.  Delusions of guilt 
4 Hears accusatory or denunciatory voices and/or experiences 
threatening visual hallucinations 
 
3. Suicide 
0     Absent 
1     Feels life is not worth living 
2 Wishes he were dead or any thoughts of possible death to self 
3 Suicide ideas or gesture 
4 Attempts at suicide (any serious attempt rates 4) 
 
4.    Insomnia - Early 
0 No difficulty falling asleep 
1 Complains of occasional difficulty falling asleep i.e., more than 
½ hour 
2 Complains of nightly difficulty falling asleep 
 
5.    Insomnia - Middle  
0 No difficulty 
1 Patient complains of being restless and disturbed during the 
night 
2 Waking during the night – any getting out of bed rates 2 
(except for purposes of voiding) 
 
6.    Insomnia - Late 
0 No difficulty 
1 Waking in early hours of the morning but goes back to sleep 
2 Unable to fall asleep again if gets out of bed 
 
7.    Work and Activities 
0 No difficulty 
1 Thoughts and feelings of incapacity, fatigue or weakness 
related to activities; work or hobbies 
2 Loss of interest in activity; hobbies or work – either directly 
reported by patient, or indirect in listlessness, indecision and 
vacillation (feels he has to push self to work or activities) 
3 Decrease in actual time spent in activities or decrease in 
productivity.  In hospital, rate 3 if patient does not spend at 
least three hours a day in activities (hospital job or hobbies) 
exclusive of ward chores. 
4 Stopped working because of present illness.  In hospital, rate 4 
if patient engages in no activities except ward chores, or if 
patient fails to perform ward chores unassisted. 
 
8.    Retardation 
       (slowness of thought and speech; impaired ability to concentrate;  
       decreased motor activity) 
0 Normal speech and thought 
1 Slight retardation at interview 
2 Obvious retardation at interview 
3 Interview difficult 







9.   Agitation 
0 None 
1 “Playing with” hand, hair, etc. 
2 Hand-wringing, nail-biting, biting of lips 
 
10.  Anxiety - Psychic 
0 No difficulty 
1 Subjective tension and irritability 
2 Worrying about minor matters 
3 Apprehensive attitude apparent in face or speech 
4 Fears expressed without questioning 
 
11.  Anxiety - Somatic 
       0     Absent      Physiological concomitants of anxiety such as:  
       1     Mild      Gastrointestinal - dry mouth, wind, indigestion, 
    2     Moderate      diarrhea, cramps, belching 
       3     Severe      Cardiovascular – palpitations, headaches 
4     Incapacitating  Respiratory - hyperventilation, sighing 
                                Urinary frequency 
                                Sweating 
 
12.  Somatic Symptoms - Gastrointestinal 
0 None 
1 Loss of appetite but eating without staff encouragement.  
Heavy feelings in abdomen.   
2 Difficulty eating without staff urging.  Requests or requires  
laxatives or medications for bowels or medication for G.I.  
symptoms.  
 
13.  Somatic Symptoms - General 
0 None 
1 Heaviness in limbs, back or head, backaches, headache, 
muscle aches, loss of energy and fatigability 
2 Any clear-cut symptom rates 2 
 
14.  Genital Symptoms 
       0     Absent          0     Not ascertained 
       1     Mild                      Symptoms such as:  loss of libido, 
       2     Severe                 menstrual disturbances 
 
15.  Hypochondriasis 
0 Not present 
1 Self-absorption (bodily) 
2 Preoccupation with health 
3 Frequent complaints, requests for help, etc. 
4 Hypochondriacal delusions 
 
16.  Loss of Weight 
       A.    When Rating by History: 
0      No weight loss 
1      Probable weight loss associated with present illness 
2      Definite (according to patient) weight loss 
 
   B.   On Weekly Ratings by Ward Psychiatrist, When Actual  
          Changes are Measured:  
0 Less than 1 lb. weight loss in week 
1 Greater than 1 lb. weight loss in week 
2 Greater than 2 lb. weight loss in week 
 
17.  Insight        
    0     Acknowledges being depressed and ill 
1 Acknowledges illness but attributes cause to bad food, 
climate, overwork, virus, need for rest, etc. 

















  Patient Name:______________________________________________________________                                              Date:_____________________ 
                                  
                                                  Hamilton Rating Scale for Depression (17-items) 
 
Instructions:  For each item select the “cue” which best characterizes the patient during the past week.   
 





Citation:  Hamilton M:  A rating scale for depression.  Journal of Neurology, Neurosurgery and  



































































UNIFIED PARKINSON'S DISEASE RATING SCALE 
I. MENTATION, BEHAVIOR AND MOOD 
0 = None.
1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties.
2 = Moderate memory loss, with disorientation and moderate difficulty handling complex problems. Mild but definite 
impairment of function at home with need of occasional prompting.
3 = Severe memory loss with disorientation for time and often to place. Severe impairment in handling problems.
4 = Severe memory loss with orientation preserved to person only. Unable to make judgements or solve problems. 
Requires much help with personal care. Cannot be left alone at all.
1. Intellectual Impairment
 (Due to dementia or drug intoxication)
0 = None.
1 = Vivid dreaming.
2 = "Benign" hallucinations with insight retained.
3 = Occasional to frequent hallucinations or delusions; without insight; could interfere with daily activities.
4 = Persistent hallucinations, delusions, or florrid psychosis. Not able to care for self.
2. Thought Disorder
1 = Periods of sadness or guilt greater than normal, never sustained for days or weeks.
2 = Sustained depression (1 week or more).
3 = Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss of interest).
4 = Sustained depression with vegetative symptoms and suicidal thoughts or intent.
3. Depression
0 = Normal.
1 = Less assertive than usual; more passive.
2 = Loss of initiative or disinterest in elective (nonroutine) activities.
3 = Loss of initiative or disinterest in day to day (routine) activities.
4 = Withdrawn, complete loss of motivation.
4. Motivation/Initiative
II. ACTIVITIES OF DAILY LIVING (for both "on" and "off")
0 = Normal.
1 = Mildly affected. No difficulty being understood.
2 = Moderately affected. Sometimes asked to repeat statements.
3 = Severely affected. Frequently asked to repeat statements.
4 = Unintelligible most of the time.
5. Speech
0 = Normal.
1 = Slight but definite excess of saliva in mouth; may have nighttime drooling.
2 = Moderately excessive saliva; may have minimal drooling.
3 = Marked excess of saliva with some drooling.
4 = Marked drooling, requires constant tissue or handkerchief.
6. Salivation
0 = Normal.
1 = Rare choking.
2 = Occasional choking.
3 = Requires soft food.
4 = Requires NG tube or gastrotomy feeding.
7. Swallowing
0 = Normal.
1 = Slightly slow or small.
2 = Moderately slow or small; all words are legible.
3 = Severely affected; not all words are legible.
4 = The majority of words are not legible.
8. Handwriting
0 = Normal.
1 = Somewhat slow and clumsy, but no help needed.
2 = Can cut most foods, although clumsy and slow; some help needed.
3 = Food must be cut by someone, but can still feed slowly.
4 = Needs to be fed.
9. Cutting food and handling utensils
0 = Normal.
1 = Somewhat slow, but no help needed.
2 = Occasional assistance with buttoning, getting arms in sleeves.




1 = Somewhat slow, but no help needed.
2 = Needs help to shower or bathe; or very slow in hygienic care.
3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom.
4 = Foley catheter or other mechanical aids.
11. Hygiene
0 = Normal.
1 = Somewhat slow and clumsy, but no help needed.
2 = Can turn alone or adjust sheets, but with great difficulty.
3 = Can initiate, but not turn or adjust sheets alone.
4 = Helpless.
12. Turning in bed and adjusting bed clothes
0 = None.
1 = Rare falling.
2 = Occasionally falls, less than once per day.
3 = Falls an average of once daily.
4 = Falls more than once daily.
13. Falling (unrelated to freezing)
0 = None.
1 = Rare freezing when walking; may have starthesitation.
2 = Occasional freezing when walking.
3 = Frequent freezing. Occasionally falls from freezing.
4 = Frequent falls from freezing.
14. Freezing when walking
0 = Normal.
1 = Mild difficulty. May not swing arms or may tend to drag leg.
2 = Moderate difficulty, but requires little or no assistance.
3 = Severe disturbance of walking, requiring assistance.
4 = Cannot walk at all, even with assistance.
15. Walking
 (Symptomatic complaint of tremor in any part of body.)
0 = Absent.
1 = Slight and infrequently present.
2 = Moderate; bothersome to patient.
3 = Severe; interferes with many activities.
4 = Marked; interferes with most activities.
16. Tremor
0 = None.
1 = Occasionally has numbness, tingling, or mild aching.
2 = Frequently has numbness, tingling, or aching; not distressing.
3 = Frequent painful sensations.
4 = Excruciating pain.
17. Sensory complaints related to parkinsonism
III. MOTOR EXAMINATION 
0 = Normal.
1 = Slight loss of expression, diction and/or volume.
2 = Monotone, slurred but understandable; moderately impaired.




1 = Minimal hypomimia, could be normal "Poker Face".
2 = Slight but definitely abnormal diminution of facial expression
3 = Moderate hypomimia; lips parted some of the time.
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted 1/4 inch or more.
19. Facial Expression
 
(head, upper and lower extremities)
0 = Absent.
1 = Slight and infrequently present.
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present.
3 = Moderate in amplitude and present most of the time.
4 = Marked in amplitude and present most of the time.
20. Tremor at rest 
0 = Absent.
1 = Slight; present with action.
2 = Moderate in amplitude, present with action.
3 = Moderate in amplitude with posture holding as well as action.
4 = Marked in amplitude; interferes with feeding.
21. Action or Postural Tremor of hands
(Judged on passive movement of major joints with patient relaxed in sitting position. Cogwheeling to be 
ignored.)
0 = Absent.
1 = Slight or detectable only when activated by mirror or other movements.
2 = Mild to moderate.
3 = Marked, but full range of motion easily achieved.
4 = Severe, range of motion achieved with difficulty.
22. Rigidity 
(Patient taps thumb with index finger in rapid succession.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.
4 = Can barely perform the task.
23. Finger Taps 
(Patient opens and closes hands in rapid succesion.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.
4 = Can barely perform the task.
24. Hand Movements 
(Pronation-supination movements of hands, vertically and horizontally, 
with as large an amplitude as possible, both hands simultaneously.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.
4 = Can barely perform the task.
25. Rapid Alternating Movements of Hands 
(Patient taps heel on the ground in rapid succession picking up entire leg. Amplitude should be at least
3 inches.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.
4 = Can barely perform the task.
26. Leg Agility 
(Patient attempts to rise from a straightbacked chair, with arms folded across chest.)
0 = Normal.
1 = Slow; or may need more than one attempt.
2 = Pushes self up from arms of seat.
3 = Tends to fall back and may have to try more than one time, but can get up without help.
4 = Unable to arise without help.
27. Arising from Chair 
0 = Normal erect.
1 = Not quite erect, slightly stooped posture; could be normal for older person.
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side.
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side.
4 = Marked flexion with extreme abnormality of posture.
28. Posture
0 = Normal.
1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or propulsion.
2 = Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or propulsion.
3 = Severe disturbance of gait, requiring assistance.




(Response to sudden, strong posterior displacement produced by pull on shoulders while patient 
erect with eyes open and feet slightly apart. Patient is prepared.)
0 = Normal.
1 = Retropulsion, but recovers unaided.
2 = Absence of postural response; would fall if not caught by examiner.
3 = Very unstable, tends to lose balance spontaneously.
4 = Unable to stand without assistance.
30. Postural Stability 
(Combining slowness, hesitancy, decreased armswing, small amplitude, and 
poverty of movement in general.)
0 = None.
1 = Minimal slowness, giving movement a deliberate character; could be normal for some persons. Possibly reduced 
amplitude.
2 = Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some reduced 
amplitude.
3 = Moderate slowness, poverty or small amplitude of movement.
4 = Marked slowness, poverty or small amplitude of movement.
31. Body Bradykinesia and Hypokinesia 
IV. COMPLICATIONS OF THERAPY (In the past week)
A. DYSKINESIAS
 (Historical information.) 
0 = None
1 = 1-25% of day.
2 = 26-50% of day.
3 = 51-75% of day.
4 = 76-100% of day.
32. Duration: What proportion of the waking day are dyskinesias present?
(Historical information; may be modified by office examination.)
0 = Not disabling.
1 = Mildly disabling.
2 = Moderately disabling.
3 = Severely disabling.
4 = Completely disabled.
33. Disability: How disabling are the dyskinesias?













36. Are "off" periods predictable?
0 = No
1 = Yes
37. Are "off" periods unpredictable?
0 = No
1 = Yes
38. Do "off" periods come on suddenly, within a few seconds?
0 = None
1 = 1-25% of day.
2 = 26-50% of day.
3 = 51-75% of day.
4 = 76-100% of day.




40. Does the patient have anorexia, nausea, or vomiting?
0 = No
1 = Yes
41. Any sleep disturbances, such as insomnia or hypersomnolence?
( Record the patient's blood pressure, height and weight on the scoring form) 
0 = No
1 = Yes
42. Does the patient have symptomatic orthostasis?
V. MODIFIED HOEHN AND YAHR STAGING 
STAGE 0 = No signs of disease.
STAGE 1 = Unilateral disease.
STAGE 1.5 = Unilateral plus axial involvement.
STAGE 2 = Bilateral disease, without impairment of balance.
STAGE 2.5 = Mild bilateral disease, with recovery on pull test.
STAGE 3 = Mild to moderate bilateral disease; some postural instability; physically independent.
STAGE 4 = Severe disability; still able to walk or stand unassisted.
STAGE 5 = Wheelchair bound or bedridden unless aided.
VI. SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE 
100% = Completely independent. Able to do all chores without slowness, difficulty or impairment. Essentially normal. 
Unaware of any difficulty.
90% = Completely independent. Able to do all chores with some degree of slowness, difficulty and impairment. Might 
take twice as long. Beginning to be aware of difficulty.
80% = Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness.
70% = Not completely independent. More difficulty with some chores. Three to four times as long in some. Must spend 
a large part of the day with chores.
60% = Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; some impossible.
50% = More dependent. Help with half, slower, etc. Difficulty with everything.
40% = Very dependent. Can assist with all chores, but few alone.
30% = With effort, now and then does a few chores alone or begins alone. Much help needed.
20% = Nothing alone. Can be a slight help with some chores. Severe invalid.
10% = Totally dependent, helpless. Complete invalid.
0% = Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden.
Beck's Depression Inventory 
This depression inventory can be self-scored. The scoring scale is at the end of the questionnaire. 
1. 
0  I do not feel sad. 
1  I feel sad 
2  I am sad all the time and I can't snap out of it. 
3  I am so sad and unhappy that I can't stand it. 
2. 
0  I am not particularly discouraged about the future. 
1  I feel discouraged about the future. 
2  I feel I have nothing to look forward to. 
3  I feel the future is hopeless and that things cannot improve. 
3. 
0 I do not feel like a failure. 
1  I feel I have failed more than the average person. 
2  As I look back on my life, all I can see is a lot of failures. 
3  I feel I am a complete failure as a person. 
4. 
  0 I get as much satisfaction out of things as I used to. 
            1  I don't enjoy things the way I used to. 
            2  I don't get real satisfaction out of anything anymore. 
            3  I am dissatisfied or bored with everything. 
5. 
           0  I don't feel particularly guilty 
           1  I feel guilty a good part of the time. 
           2  I feel quite guilty most of the time. 
           3  I feel guilty all of the time. 
6. 
          0  I don't feel I am being punished. 
          1  I feel I may be punished. 
          2  I expect to be punished. 
          3  I feel I am being punished. 
7. 
         0  I don't feel disappointed in myself. 
         1  I am disappointed in myself. 
         2  I am disgusted with myself. 
         3  I hate myself. 
8. 
         0  I don't feel I am any worse than anybody else. 
         1  I am critical of myself for my weaknesses or mistakes. 
         2  I blame myself all the time for my faults. 
         3  I blame myself for everything bad that happens. 
9. 
       0   I don't have any thoughts of killing myself. 
       1   I have thoughts of killing myself, but I would not carry them out. 
       2   I would like to kill myself.  
       3  I would kill myself if I had the chance. 
10. 
       0   I don't cry any more than usual. 
       1   I cry more now than I used to. 
       2   I cry all the time now. 
       3   I used to be able to cry, but now I can't cry even though I want to. 
11. 
       0   I am no more irritated by things than I ever was. 
       1   I am slightly more irritated now than usual. 
       2   I am quite annoyed or irritated a good deal of the time. 
       3   I feel irritated all the time. 
12. 
        0   I have not lost interest in other people. 
        1   I am less interested in other people than I used to be. 
        2   I have lost most of my interest in other people. 
        3   I have lost all of my interest in other people. 
13. 
        0   I make decisions about as well as I ever could. 
        1   I put off making decisions more than I used to. 
        2   I have greater difficulty in making decisions more than I used to. 
        3   I can't make decisions at all anymore. 
14. 
        0   I don't feel that I look any worse than I used to. 
        1   I am worried that I am looking old or unattractive. 
        2   I feel there are permanent changes in my appearance that make me look    
                        unattractive 
        3   I believe that I look ugly. 
15. 
        0   I can work about as well as before. 
        1   It takes an extra effort to get started at doing something. 
        2   I have to push myself very hard to do anything. 
        3   I can't do any work at all. 
16. 
        0   I can sleep as well as usual. 
        1   I don't sleep as well as I used to. 
        2   I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. 
        3   I wake up several hours earlier than I used to and cannot get back to sleep. 
 
17. 
       0   I don't get more tired than usual. 
       1   I get tired more easily than I used to. 
       2   I get tired from doing almost anything. 
       3   I am too tired to do anything. 
18. 
       0   My appetite is no worse than usual. 
       1  My appetite is not as good as it used to be. 
       2   My appetite is much worse now. 
       3   I have no appetite at all anymore. 
19. 
      0   I haven't lost much weight, if any, lately. 
      1  I have lost more than five pounds. 
      2   I have lost more than ten pounds. 






      0   I am no more worried about my health than usual. 
      1   I am worried about physical problems like aches, pains, upset stomach, or   
             constipation. 
      2   I am very worried about physical problems and it's hard to think of much else. 
      3   I am so worried about my physical problems that I cannot think of anything else.  
21. 
      0   I have not noticed any recent change in my interest in sex. 
      1   I am less interested in sex than I used to be. 
      2   I have almost no interest in sex. 
      3   I have lost interest in sex completely. 
INTERPRETING THE BECK DEPRESSION INVENTORY 
Now that you have completed the questionnaire, add up the score for each of the twenty-one 
questions by counting the number to the right of each question you marked. The highest possible 
total for the whole test would be sixty-three. This would mean you circled number three on all 
twenty-one questions. Since the lowest possible score for each question is zero, the lowest 
possible score for the test would be zero. This would mean you circles zero on each question. 
You can evaluate your depression according to the Table below. 
Total Score____________________Levels of Depression 
1-10____________________These ups and downs are considered normal  
11-16___________________ Mild mood disturbance  
17-20___________________Borderline clinical depression  
21-30___________________Moderate depression  
31-40___________________Severe depression  
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